WO2008021886A2 - Ablative cardiac catheter system - Google Patents
Ablative cardiac catheter system Download PDFInfo
- Publication number
- WO2008021886A2 WO2008021886A2 PCT/US2007/075487 US2007075487W WO2008021886A2 WO 2008021886 A2 WO2008021886 A2 WO 2008021886A2 US 2007075487 W US2007075487 W US 2007075487W WO 2008021886 A2 WO2008021886 A2 WO 2008021886A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ablation probe
- catheter
- cryogenic
- transducer
- guide wire
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N7/022—Localised ultrasound hyperthermia intracavitary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B18/0206—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques ultrasonic, e.g. for destroying tissue or enhancing freezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00292—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
- A61B2017/003—Steerable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
Definitions
- the present invention relates to an ablative apparatus that can be used to treat atrial fibrillation and/or other cardiac arrhythmias by ablating cardiac tissue.
- Atrial fibrillation is the most common arrhythmia (abnormal beating of the heart) encountered in clinical practice.
- AF is a specific type of arrhythmia in which an abnormal beating of the heart originates in one of the heart's two atrium. Increasing in prevalence, an estimated 2.2 million Americans suffer from AF.
- ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Underlying one out of every six strokes, AF doubles the rate of morbidity compared to patients with normal sinus rhythm.
- AF is a serious disorder requiring medical intervention.
- Administering drugs that alter the electrical properties of atrial myocardium has been effective in treating less severe cases of AF. (Hurst's the heart, page 836)
- warfarin is known to induce several adverse interactions with other medications commonly prescribed to elderly patients, who are at increased risk of developing AF.
- AF originates in regions of myocardium contracting, or beating, out of step with the rest of the heart.
- Heart cells contract in response to electrical stimulation.
- the electrical stimulation signaling a contraction originates from the sinus node (the heart's natural pace maker) and spreads in an organized manner across the heart.
- the sinus node the heart's natural pace maker
- a region of myocardium elicits a mistimed contraction, or heart beat, on its own or in response to an electrical signal generated from somewhere other than the sinus node.
- the mistimed contraction spreads across the heart, inducing contractions in neighboring regions of the heart.
- Heart surgery performed by means of catheter involves, in its basic conception, the insertion of a catheter either into a patient's vein or chest cavity. The catheter is then advanced to the heart. When the catheter is inserted into a patient's vein, the catheter is advanced into one of the heart's four chambers. When the catheter in inserted into a patient's chest, the catheter is advanced to the outer walls of the patient's heart. After the catheter reaches the patient's heart the surgeon utilizes the catheter to ablate, damage or, kill cardiac tissue.
- the ideal catheter induced lesion is one that is created from the epicardium (outside) of the beating heart, is able to go through epicardial fat, is performed rapidly over variable lengths, is transmural, causes no collateral injury, and can be applied at any desired anatomic location.
- Ablating cardiac tissue by heating the tissue to 50 degrees Celsius has become the preferred means of inducing lesions (Williams et al., 2004).
- Cardiac catheters employing a variety of thermal ablative energy sources have been developed, none of which are capable of inducing an ideal lesion.
- Radio frequency catheters have a difficult time creating ablations through the epicardial fat surrounding the heart. Furthermore, inducing deep lesions with radio frequency is not possible without inflicting collateral damage resulting from surface burning and steam popping.
- Steam popping is the phenomenon in which cells become heated to such a point that their internal fluids begin to boil, producing steam that bursts the cell. Simultaneously cooling the site of radio frequency administration reduces the incidence of surface burns but does not reduce the risk of steam popping.
- Lasers have also been applied as an ablative energy source within catheters. Although high powered lasers carry a high risk of crater formation at the site of application, low energy lasers produce lesions with a depth related to the duration of application. (Cummings et al., 2005) Therefore, the ideal rapid induction of a deep lesion is not possible with laser catheters without the risk of crater formation and collateral damage.
- high intensity ultrasound has been predicted to be an advantageous source of ablative energy in catheters.
- properly focusing ultrasound energy requires exact knowledge as to the depth of the lesion and the position of the catheter, which may not be possible in a closed heart or closed chest procedure.
- high intensity ultrasound is capable of inducing internal cavitations resulting in apoptosis (a delayed form of cellular death) as it passes through cells on its way to the desired location of the lesion. Consequently, ultrasound induced lesions, though fast, are not free from the complications of collateral damage. Furthermore, collateral damage may not become apparent until sometime after the procedure.
- cryoablative catheters are not without their limitations.
- cryoablative catheters are not capable of rapidly inducing lesions.
- the ablative apparatus comprises an ablation probe, a transducer capable of ultrasonically driving the ablation probe in contact with the proximal end of the ablation probe, a guide wire secured at one end to the transducer and/or ablation probe, electrical leads running along the guide wire and connected to electrodes capable of exposing piezo ceramic discs within the transducer to an alternating voltage, a catheter encasing the ablation probe, transducer, and at least a portion of the guide wire, and a handle secured to the end of the guide wire opposite the transducer.
- the catheter is composed of a biologically compatible polymer.
- the ablation probe located at the distal end of the catheter system may comprise a proximal surface, a distal surface opposite the proximal surface, at least one radial surface extending between the proximal surface and the distal surface, and at least one abrasive member on at least one surface other than the proximal surface.
- the ablation probe may be contained within a pocket at the distal end of the catheter.
- the ablation probe may be removed from the pocket, as to expose the abrasive member(s).
- the ablation probe When the transducer in contact with the proximal surface of the ablation probe is activated by supplying it with an electrical current, the ablation probe becomes driven by ultrasonic energy generated by the transducer and begins to vibrate. As the ablation probe vibrates, the abrasive members on the ablation probe scratch tissues with which the members come in contact, as to create an abrasion in the tissues. Physically inducing an abrasion within a tissue, the vibrating ablation probe is capable of mechanically ablating tissues. When the ablation probe is advanced to the heart, mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The exposed myocardium may then be subjected to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
- Flowing a cryogenic material through the catether, as to deliver cryogenic energy to the ablation probe, to a region of the catheter in close proximity to the ablation probe, and/or to another region of the catheter, may enable cryoablation.
- Lumens running substantially the length of the catheter and joined by a junction may enable a cryogenic material to flow through the catheter.
- Such lumens may comprise a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter, through which a cryogenic material flows from the proximal end of the catheter towards its distal end.
- a cryogenic exhaust lumen running substantially the length of the catheter and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the catheter may permit a cryogenic material to flow towards the proximal end of the catheter.
- a junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens.
- the cryogenic material may be prevented from exiting the catheter by a partition distal to the junction isolating the intake lumen and exhaust lumen from the remaining distal portions of the catheter.
- a cryogenic material may be flowed through the catheter by first flowing through an intake lumen and towards the distal end of the catheter. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the catheter, the cryogenic material then flows through the exhaust lumen and back towards the proximal end of the catheter.
- Cryogenic ablation may also be enabled by flowing a cryogenic material through the guide wire.
- lumens running substantially the length of the guide wire and joined by a junction may enable a cryogenic material to flow through the guide wire.
- Such lumens may comprise cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the wire, through which a cryogenic material flows from the proximal end of the guide wire towards its distal end.
- a cryogenic exhaust lumen running substantially the length of the wire and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the wire may permit a cryogenic material to flow towards the proximal end of the wire.
- a junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens.
- the junction connecting the lumens may comprise a chamber internal to the ablation probe into which the intake lumen and exhaust lumen open.
- a cryogenic material may be flowed through the guide wire by first flowing through an intake lumen and towards die distal end of the wire. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the wire, the cryogenic material then flows through the exhaust lumen and back towards the distal end of the catheter.
- the ablative apparatus enables the surgical treatment of cardiac arrhythmias by providing a means to mechanically, ultrasonically, and/or cryogenically ablate myocardial tissue.
- a surgeon utilizing the disclosed ablative apparatus will be able to select the appropriate ablative means or combination of ablative means best suited for the patient's particular pathology and the type of lesion the surgeon wishes to induce.
- Driving the ablation probe with ultrasound energy generated by the transducer enables a surgeon to quickly induce surface abrasions of various depths by adjusting the pulse frequency and duration of the driving ultrasound. This may prove advantageous when the surgeon wishes to induce a lesion at a specific location with minimal collateral injury, such as during AV nodal modification.
- the ablative apparatus may enable the surgeon to cryoablate tissue without the ablation probe adhering to the tissue being ablated. As such, the surgeon may be able to easily move the probe during ablation.
- the ablation probe may be moved during the induction of a lesion by including control means for steering and/or rotating the ablation probe within the handle.
- the probe's mobility during cryoablation could allow the surgeon to create linear lesions in cardiac tissue or isolating lesions in vessel walls.
- the ablative apparatus may give the surgeon greater control over the lesion induced. Furthermore, it has been hypothesized that the administration of low frequency ultrasound and cryoablation induces the release of several healing factors from the targeted tissue.
- ultrasonically vibrating the ablation probe during cryoablation may improve mobility of the ablation probe and possibly induce healing.
- dually administering ultrasonic energy and cryogenic energy may protect surface tissue during the administration of a deep lesion, thereby limiting collateral damage.
- the co-administration of ultrasonic energy will warm the surface tissue preventing it from freezing.
- administering cryogenic energy during the induction of a deep lesion with ultrasonic energy will cool surface tissue thereby protecting it from ablative cavitation, possibly by reducing molecular movement.
- the ablative apparatus may also enable the surgeon to deliver various drugs and/or other pharmacological compounds to the location of the lesion and/or other locations.
- Combining drug delivery with the application of ultrasound energy may assist drug delivery and drug penetration into the targeted tissue.
- Delivering an antithrombolytic during the induction of a lesion may reduce the likelihood of clot formation, especially during mechanical ablation.
- the surgeon may also choose to expedite healing by delivering various healing and/or growth factors to the site of the lesion.
- Drug delivery may be accomplished by coating the ablation probe with a drug or other pharmacological compound. When so coated, driving the ablation probe with ultrasonic energy may liberate the drug coating from the probe and embed it within the targeted tissue.
- the catheter may contain a drug lumen and/or reservoir permitting the administration of a drug to internal locations of the patient's body.
- Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
- Figure 3 depicts an alternative embodiment of the ablative apparatus.
- Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
- Figures 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, a radial surface extending between the proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface.
- Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
- ablative apparatus that may be used to treat atrial fibrillation and other arrhythmias. Perferred embodiments of the ablative apparatus are illustrated in the figures and described in detail below. Figure 1 depicts a possible embodiment of the ablative apparatus.
- the ablative apparatus comprises an ablation probe 101, a transducer 102 capable of capable of ultrasonically driving the ablation probe 101 in contact with the proximal surface 103 of ablation probe 101, a guide wire 104 secured at one end to transducer 102, electrical leads 105 running along guide wire 104 and connected to electrodes 113 capable of exposing piezo ceramic disc 112 within transducer 102 to an alternating voltage, a catheter 106 encasing ablation probe 101, transducer 102, and at least a portion of guide wire 104, and a handle 107 secured to the end of guide wire 104 opposite transducer 102.
- catheter 106 is composed of a biologically compatible polymer.
- Handle 107 may contain control means 108 for steering and/or rotating ablation probe 101. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which are incorporated herein by reference.
- handle 108 may provide a means of rotating ablation probe 101. When rotated, ablation probe 101 moves in a circular motion similar to the manner in which the hands of clock move about its face. Rotation of ablation probe 101 can be accomplished by the surgeon turning handle 107 with his wrist as if he were using a screw driver. Extending from handle 107, through catheter 106, to transducer 102, guide wire 104 provides rigidity to catheter 106. Guide wire 104 may also carry electrical leads 105 down catheter 106 to transducer 101. Transmitting an electrical current generated by generator 108 to transducer 102, electrical leads 105 energize transducer 102 as to drive ablation probe 101.
- Ablation probe 101 comprises a distal surface 109, a proximal surface 103 opposite the distal surface 109, at least one radial surface 110 extending between distal surface 109 and proximal surface 103, and abrasive members 111 on radial surface 110.
- Transducer 102 in contact with the proximal surface 103 of ablation probe 101, comprises a stack of piezo ceramic discs 112 arranged in a manner similar to that of a roll of coins.
- piezo ceramic discs 112 Running from generator 108 to electrodes 113, electrical leads 105 carry a current to electrodes 113 as to expose piezo ceramic discs 112 to an alternating voltage. So energizing transducer 102 induces the expansion and contraction of piezo ceramic discs 112, as to drive ablation probe 101. Expanding and contracting, piezo ceramic discs 112 apply ultrasonic energy to ablation probe 101. Applying ultrasonic energy to probe 101 may induce a vibrating or oscillating movement of probe 101. As ablation probe 101 moves, abrasive members 111 scratch tissues with which the members 111 contact, as to create an abrasion in the tissue.
- Back drive 114 located at the proximal end of transducer 102, stabilizes ablation probe 101 when it is driven by ultrasound energy generated by transducer 102.
- catheter 106 encasing ablation probe 101, transducer 102, and a portion of guide wire 104, contains a pocket 115 at its distal end 122 encasing ablation probe 101. Encasing ablation probe 101 within pocket 115 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 111 damaging tissue.
- ablation probe 101 may be removed from pocket 115, as to expose abrasive members 111, by firmly pulling catheter 106 towards handle 107.
- sealed tip 116 may contain single or multiple slits 117. Slit(s) 117 may completely or partially penetrate sealed tip 116.
- Advancing the ablative apparatus into and through the patient's body with ablation probe 101 retracted within pocket 115 protects the patient's internal tissues from damage by abrasive members 111.
- the surgeon may retract catheter 106, exposing ablation probe 101.
- the surgeon may then mechanically ablate the target tissue by driving ablation probe 101 with ultrasound energy generated by transducer 102.
- the surgeon may not expose ablation probe 101, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
- flowing a cryogenic material through catheter 106 may enable cryoablation.
- a cryogenic material may be delivered to catheter 106 from a cryogenic storage and retrieval unit b in fluid communication with cryogenic intake lumen 119 via cryogenic feed tubing 120, attached to the proximal end intake lumen 119. Originating at the proximal end 121 of catheter 106 and running substantially the length of catheter 106, cryogenic intake lumen 119 permits a cryogenic material entering catheter 106 from storage and retrieval unit 118 to flow towards the distal end 122 of catheter 106.
- the cryogenic material flows through a junction connecting intake lumen 119 with exhaust lumen 123 located at the distal end of the intake lumen 119 and exhaust lumen 123.
- the specific junction depicted in Figure 1 comprises a port 124 between intake lumen 119 and exhaust lumen 123.
- Running substantially the length of catheter 106, substantially parallel to intake lumen 119, and terminating at the proximal end 121 of catheter 106, exhaust lumen 123 permits the cryogenic material to flow towards proximal end 121 of catheter 106.
- cryogenic material After reaching the proximal end 121 of catheter 106, the cryogenic material is returned to storage and retrieval unit 118 via cryogenic exhaust tubing 125 attached to the proximal end exhaust lumen 123, which is in fluid communication with storage and retrieval unit 118 and exhaust lumen 123.
- Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units.
- the storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
- a partition 126 distal to port 124 isolates intake lumen 119 and exhaust lumen 123 from pocket 115.
- catheter 106 In order to prevent catheter 106 from becoming rigid and inflexible as cryogenic material flows through it, catheter 106, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 106, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 104.
- FIGS. 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
- Figure 2A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 extended from pocket 115.
- Figure 2B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 retracted into pocket 115.
- catheter 106 comprises a cryogenic intake lumen 119 and an exhaust lumen 123 (obscured in the present view by intake lumen 119) connected by ports 124.
- the flow of a cryogenic material from the proximal end 121 of catheter 106 towards the distal end 122 of catheter 106 through intake lumen 119, across ports 124, and then back towards the proximal end 122 through exhaust lumen 123 cools pocket 115.
- the cryogenic material flowing through the catheter may also cool ablation probe 101 and/or transducer 102.
- the junction between the intake lumen 119 and exhaust lumen 123 may comprise a chamber.
- FIG. 3 depicts an alternative embodiment of the ablative apparatus.
- the depicted embodiment of the ablative apparatus comprises an ablation probe 301, a transducer 302 capable of ultrasonically driving the ablation probe 301 in contact with the proximal surface 303 of ablation probe 301, a guide wire 304 secured at one end to ablation probe 301 and/or transducer 302, electrical leads 305 running along guide wire 304 and connected to electrodes 313 capable exposing piezo ceramic disc 312 within transducer 302 to an alternating voltage, a catheter 306 encasing ablation probe 301, transducer 302, and at least a portion of guide wire 304, and a handle 307 secured to the end of guide wire 304 opposite ablation probe 301.
- Handle 307 may contain control means 308 for steering and/or rotating ablation probe 301. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which were previously incorporated herein by reference.
- handle 308 may provide a means of rotating ablation probe 301. As with the embodiment depicted in Figure 1, the rotation of ablation probe 301 can be accomplished by the surgeon turning handle 307 with his wrist as if he were using a screw driver.
- guide wire 304 Extending from handle 307, through catheter 306, to ablation probe 301, guide wire 304 provides rigidity to catheter 306. Guide wire 304 may also carry electrical leads 305 down catheter 306 to transducer 302.
- Ablation probe 301 comprises a distal surface 309, a proximal surface 303 opposite the distal surface 309, at least one radial surface 310 extending between distal surface 309 and proximal surface 303, and abrasive members 311 on radial surface 310.
- Transducer 302 in contact with the proximal surface 303 of ablation probe 301 and encircling guide wire 304, comprises a stack of piezo ceramic discs 312 arranged in a manner similar to that of a roll of coins.
- So energizing transducer 302 induces the expansion and contraction of piezo ceramic discs 312, as to drive ablation probe 301.
- piezo ceramic discs 312 apply ultrasonic energy to ablation probe 301. Applying ultrasonic energy to probe 301 may induce a vibrating or oscillating movement of probe 301.
- abrasive members 311 scratch tissues with which the members 311 come in contact, as to create an abrasion in the tissue.
- catheter 306, encasing ablation probe 301, transducer 302, and a portion of guide wire 304, contains a pocket 315 at its distal end 322 encasing ablation probe 301.
- Encasing ablation probe 301 within pocket 315 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 311 damaging tissue.
- ablation probe 301 may be removed from pocket 315, as to expose abrasive members 311, by firmly pulling catheter 306 towards handle 307.
- sealed tip 316 may contain single or multiple slits 317. Slit(s) 317 may completely or partially penetrate sealed tip 316.
- firmly pulling handle 307 away from the patient while holding catheter 306 stationary returns ablation probe 301 to the inside of pocket 315.
- Advancing the ablative apparatus into and through the patient's body with ablation probe 301 retracted within pocket 315 protects the patient's internal tissues from damage by abrasive members 311.
- the surgeon may retract catheter 306, exposing ablation probe 301. The surgeon may then mechanically ablate the target tissue by driving ablation probe 301 with ultrasound energy generated by transducer 302. Alternatively, the surgeon may not expose ablation probe 301, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
- cryogenic material may be delivered to guide wire 304 from a cryogenic storage and retrieval unit 318 in fluid communication with cryogenic intake lumen 319 via cryogenic feed tubing 320, attached to the proximal end intake lumen 319. Originating at the proximal end 321 of guide wire 304 and running substantially the length of guide wire 304, cryogenic intake lumen 319 permits a cryogenic material entering guide wire 304 from storage and retrieval unit 318 to flow towards the distal end 326 of guide wire 304.
- the cryogenic material flows through a junction connecting intake lumen 319 with exhaust lumen 323 at the distal end of the intake lumen 319 and exhaust lumen 323.
- the specific junction depicted in Figure 3 comprises an expansion chamber 324 within ablation probe 301 into which intake lumen 319 and exhaust lumen 323 open.
- Running substantially the length of guide wire 304, substantially parallel to intake lumen 319, and terminating at the proximal end 321 of guide wire 304, exhaust lumen 323 permits the cryogenic material to flow towards proximal end 321 of guide wire 304.
- cryogenic material After reaching the proximal end 321 of guide wire 304, the cryogenic material is returned to storage and retrieval unit 318 via cryogenic exhaust tubing 325 attached to the proximal end exhaust lumen 323, which is in fluid communication with storage and retrieval unit 318 and exhaust lumen 323.
- Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units.
- the storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
- catheter 306 In order to prevent catheter 306 from becoming rigid and inflexible as cryogenic material flows through guide wire 304, catheter 306, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 306, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 304.
- Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
- Figure 4A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 extended from pocket 315.
- Figure 4B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 retracted into pocket 315.
- guide wire 304 comprises a cryogenic intake lumen 319 and an exhaust lumen 323 connected by expansion chamber 324.
- the junction between the intake lumen 319 and exhaust lumen 323 may comprise one or a series of ports connecting intake lumen 319 with exhaust lumen 323.
- Incorporating threading on a portion of the ablation probe and/or transducer along with corresponding threading on the internal surface of the catheter's pocket may facilitate a smooth deployment of the ablation probe from the catheter's pocket.
- the surgeon would advance the ablation probe from the pocket by rotating the guide wire and attached ablation probe. Rotating the guide wire in the opposite direction would retract the ablation probe back into the pocket.
- the ablation probe of the ablative apparatus may contain one or multiple abrasive members attached to its proximal and/or radial surfaces.
- the abrasive members may be constructed in various configurations, as depicted in Figure 5.
- Figure 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, and a radial surface extending between the proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface.
- the ablation probe 501 depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw.
- the ablation probe 504, as depicted in Figure 5B may contain abrasive members comprising a thin band 505 attached to radial surface 506 and encircling ablation probe 504.
- the abrasive member may comprise small particle 508, conceptually similar to a grain of grit on a piece of sand paper, attached to the proximal surface 509 and/or radial surface 510 of ablation probe 507. It is also possible, as indicated by ablation probe 511, depicted in Figure 5D, for the abrasive member to comprise a protrusion 512 extending from a surface of the ablation probe 511 other than proximal surface 513.
- the ablation probes depicted in Figures 5A-5D may be constructed by attaching or affixing the depicted abrasive members to their proximal and/or radial surfaces.
- the ablation probes depicted in Figures 5A-5D may be constructed such that the abrasive members are extensions of or integral with the ablation probes.
- Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
- the transducer may be comprised of a single piezo ceramic disc.
- the transducer may contain a collection of piezo ceramic discs as depicted in Figure 6.
- the transducer may contain a collection cylindrical piezo ceramic discs 601 stacked upon one another in a manner resembling a roll of coins, as depicted in Figure 6A.
- Such an arrangement may impart an axial or longitudinal displacement upon the driven ablation probe when the transducer is energized.
- the transducer may contain a pair of half cylindrical piezo ceramic discs 602 combined to form a cylinder, as depicted in Figure 6C. Such an arrangement may impart a circumferential displacement upon the driven ablation probe when the transducer is energized.
- the transducer may also contain a combination of cylindrical piezo ceramic discs 601 and half cylindrical piezo ceramic discs 602, as depicted in Figure 6B. Such a combination arrangement may impart an axial and circumferential displacement upon the driven ablation probe when the transducer is energized.
- the ultrasound transducer responsible for driving the ablation probe need not be in direct contact with the ablation probe. Instead, the transducer may be in communication with the guide wire attached to the ablation probe, driving the ablation probe through said communication.
- the transducer may be located anywhere within the ablative apparatus, including, but not limited to, the handle. The transducer may also be located elsewhere within the ablative apparatus, provided the transducer is in direct or indirect communication with the ablation probe.
- the transducer utilized in the ablative apparatus should be capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
- the recommended frequency of vibration is approximately 30 kHz to approximately 40 kHz.
- the transducer should also be capable of driving the transducer with ultrasonic energy having an intensity of at least approximately 0.1 Watts per centimeter squared.
- Pulse duration and treatment time are dependent upon the depth and type of lesion the surgeon wishes to induce. Pulsing the ultrasound energy driving the transducer by repeatedly turning the transducer on and off gives the surgeon control over lesion depth. Incorporating an ultrasound controller may permit the surgeon to control, regulate, or adjust, the pulse duration and pulse frequency of the driving ultrasound. Adjusting the pulse frequency and duration enables the surgeon to control the depth of the lesion inflicted by the ablation probe.
- the surgeon may retract the catheter as to expose the ablation probe's abrasive member(s).
- the surgeon may then mechanical induce an abrasion by driving the ablation probe with ultrasound energy generated by the transducer.
- the surgeon may not expose the ablation probe's abrasive members but rather activate the flow of cryogenic material through the ablative apparatus as to induce a lesion by means of cryoablation. If the surgeon wishes to induce a continuous lesion across a segment of cardiac tissue, the surgeon may activate the transducer as to prevent cryoadhesion of the catheter's distal end to the target tissue.
- Activating the transducer during cryoablation enables the surgeon to warm surface tissue at the site of ablation, thereby protecting surface tissue from ablation or injury.
- activating the flow of cryogenic material through the apparatus while ultrasonically inducing a lesion enables the surgeon to cool surface tissue at the site of the ablation, thereby protecting it from ablation or injury.
- Incorporating a mapping electrode placed at or near the distal end of the ablative apparatus may assist the surgeon in locating specific sites of arrhythmia.
- the mapping electrode may be located at or attached to the ablation probe.
- a mapping electrode may enable the surgeon to detect the electrical activity of the cells near the electrode. The surgeon could use the detected electrical activity to determine if the cells near the electrode are contributing to the arrhythmia.
- the surgeon may administer cryogenic energy to a region of myocardium suspected to be contributing to the patient's arrhythmia as to paralyze the tissue. If paralyzing the tissue completely or partially corrects the arrhythmia, the surgeon may then ablate the tissue with the ablation probe.
- Incorporating a temperature sensor placed at or near the distal end of the ablative apparatus may enable the surgeon to monitor the temperature at the site of the ablation.
- the sensor may be located near or attached to the ablation probe.
- Monitoring the temperature near or at the site of the ablation with the temperature sensor may assist the surgeon in avoiding burning and/or inflicting other undesirable damage or injury.
- the surgeon could stop the ablation and allow the tissue to return to a safer temperature.
- the surgeon may also adjust the ultrasound parameters as to slow the change in temperature. If the ablative procedure being performed involves die administration of cryogenic energy, the surgeon may adjust the flow of the cryogenic material through the catheter system as to slow the change in temperature.
- the ablative apparatus may also contain a drug lumen through which a drug solution or other fluid or composition may be introduced into the patient's body.
- the ablative apparatus may also contain a drug reservoir at its distal end.
- the drug reservoir may surround the ablation probe.
- the drug reservoir may be located proximal to the ablation probe.
- the drug reservoir may contain slits at its base. The slits may completely or partially penetrate the base of the drug reservoir. Retracting the catheter may then cause the ablation probe to penetrate the base of the drug reservoir and eventually the distal end of the reservoir. Traveling through the reservoir, the ablation probe may be coated with a drug.
- Suspending the drug within a viscous or gel solution may offer better coating of the ablation probe as it travels through the drug reservoir.
- Ultrasonically driving the ablation probe will cause the drug solution clinging to the ablation probe to be liberated from the ablation probe and embedded in the tissue at and surrounding the site of the lesion.
- ultrasonically driving the ablation probe while the probe is retracted may cause the release of drug from the drug reservoir.
- drug delivery during the induction of lesions may be accomplished by first coating the ablation probe with a pharmacological compound. As in the above mention embodiment, ultrasonically driving the ablation probe will liberate the drug coating compound; dispersing it into the targeted tissue.
- biologically compatible polymer refers to polymers, or plastics, that will not normally irritate or harm the body. Such polymers are familiar to those skilled in the art.
- pieo ceramic disc refers to an element composed of a ceramic material expands and contracts when exposed to an alternating voltage. Such ceramics are well known to those skilled in the art.
- energizing the transducer refers to inducing the contraction and expansion of piezo ceramic discs within the transducer by exposing the discs to an alternating voltage, as to induce the generation of ultrasonic energy.
- the term "ultrasonically driven,” as used herein, refers to causing the ablation probe to move by applying to the probe ultrasonic energy generated by a transducer in direct or indirect contract with the probe.
- the induced movement of the probe may include vibrating, oscillating, and/or other manners of motion.
- the terra "pulse duration,” as used herein, refers to the length of time the transducer is generating ultrasonic energy.
- pulse frequency refers to how often ultrasound transducer generates ultrasound during a period of time.
- mechanical ablation refers to injuring a tissue by scratching the tissue as to create an abrasion in the tissue.
- surgeon references all potential users of the disclosed ablative apparatus and does not limit the user of the apparatus to any particular healthcare or medical professional or healthcare or medical professionals in general.
- the disclosed ablative apparatus enables the surgical treatment of atrial fibrillation and/or other arrhythmias.
- the present invention relates to an ablative apparatus that can be used to treat atrial fibrillation and/or other cardiac arrhythmias by ablating cardiac tissue.
- Atrial fibrillation is the most common arrhythmia (abnormal beating of the heart) encountered in clinical practice.
- AF is a specific type of arrhythmia in which an abnormal beating of the heart originates in one of the heart's two atrium. Increasing in prevalence, an estimated 2.2 million Americans suffer from AF.
- ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Underlying one out of every six strokes, AF doubles the rate of morbidity compared to patients with normal sinus rhythm.
- AF is a serious disorder requiring medical intervention.
- Administering drugs that alter the electrical properties of atrial myocardium has been effective in treating less severe cases of AF. (Hurst's the heart, page 836)
- warfarin is known to induce several adverse interactions with other medications commonly prescribed to elderly patients, who are at increased risk of developing AF.
- AF originates in regions of myocardium contracting, or beating, out of step with the rest of the heart.
- Heart cells contract in response to electrical stimulation.
- the electrical stimulation signaling a contraction originates from the sinus node (the heart's natural pace maker) and spreads in an organized manner across the heart.
- the sinus node the heart's natural pace maker
- a region of myocardium elicits a mistimed contraction, or heart beat, on its own or in response to an electrical signal generated from somewhere other than the sinus node.
- the mistimed contraction spreads across the heart, inducing contractions in neighboring regions of the heart.
- Heart surgery performed by means of catheter involves, in its basic conception, the insertion of a catheter either into a patient's vein or chest cavity. The catheter is then advanced to the heart. When the catheter is inserted into a patient's vein, the catheter is advanced into one of the heart's four chambers. When the catheter in inserted into a patient's chest, the catheter is advanced to the outer walls of the patient's heart. After the catheter reaches the patient's heart the surgeon utilizes the catheter to ablate, damage or, kill cardiac tissue.
- the ideal catheter induced lesion is one that is created from the epicardium (outside) of the beating heart, is able to go through epicardial fat, is performed rapidly over variable lengths, is transmural, causes no collateral injury, and can be applied at any desired anatomic location.
- Ablating cardiac tissue by heating the tissue to 50 degrees Celsius has become the preferred means of inducing lesions (Williams et al., 2004).
- Cardiac catheters employing a variety of thermal ablative energy sources have been developed, none of which are capable of inducing an ideal lesion.
- Radio frequency catheters have a difficult time creating ablations through the epicardial fat surrounding the heart. Furthermore, inducing deep lesions with radio frequency is not possible without inflicting collateral damage resulting from surface burning and steam popping.
- Steam popping is the phenomenon in which cells become heated to such a point that their internal fluids begin to boil, producing steam that bursts the cell. Simultaneously cooling the site of radio frequency administration reduces the incidence of surface burns but does not reduce the risk of steam popping.
- Lasers have also been applied as an ablative energy source within catheters. Although high powered lasers carry a high risk of crater formation at the site of application, low energy lasers produce lesions with a depth related to the duration of application. (Cummings et al., 2005) Therefore, the ideal rapid induction of a deep lesion is not possible with laser catheters without the risk of crater formation and collateral damage.
- high intensity ultrasound has been predicted to be an advantageous source of ablative energy in catheters.
- properly focusing ultrasound energy requires exact knowledge as to the depth of the lesion and the position of the catheter, which may not be possible in a closed heart or closed chest procedure.
- high intensity ultrasound is capable of inducing internal cavitations resulting in apoptosis (a delayed form of cellular death) as it passes through cells on its way to the desired location of the lesion. Consequently, ultrasound induced lesions, though fast, are not free from the complications of collateral damage. Furthermore, collateral damage may not become apparent until sometime after the procedure.
- cryoablative catheters are not without their limitations.
- cryoablative catheters are not capable of rapidly inducing lesions.
- the ablative apparatus comprises an ablation probe, a transducer capable of ultrasonically driving the ablation probe in contact with the proximal end of the ablation probe, a guide wire secured at one end to the transducer and/or ablation probe, electrical leads running along the guide wire and connected to electrodes capable of exposing piezo ceramic discs within the transducer to an alternating voltage, a catheter encasing the ablation probe, transducer, and at least a portion of the guide wire, and a handle secured to the end of the guide wire opposite the transducer.
- the catheter is composed of a biologically compatible polymer.
- the ablation probe located at the distal end of the catheter system may comprise a proximal surface, a distal surface opposite the proximal surface, at least one radial surface extending between the proximal surface and the distal surface, and at least one abrasive member on at least one surface other than the proximal surface.
- the ablation probe may be contained within a pocket at the distal end of the catheter.
- the ablation probe may be removed from the pocket, as to expose the abrasive member(s).
- the ablation probe When the transducer in contact with the proximal surface of the ablation probe is activated by supplying it with an electrical current, the ablation probe becomes driven by ultrasonic energy generated by the transducer and begins to vibrate. As the ablation probe vibrates, the abrasive members on the ablation probe scratch tissues with which the members come in contact, as to create an abrasion in the tissues. Physically inducing an abrasion within a tissue, the vibrating ablation probe is capable of mechanically ablating tissues. When the ablation probe is advanced to the heart, mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The exposed myocardium may then be subjected to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
- Flowing a cryogenic material through the catether, as to deliver cryogenic energy to the ablation probe, to a region of the catheter in close proximity to the ablation probe, and/or to another region of the catheter, may enable cryoablation.
- Lumens running substantially the length of the catheter and joined by a junction may enable a cryogenic material to flow through the catheter.
- Such lumens may comprise a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter, through which a cryogenic material flows from the proximal end of the catheter towards its distal end.
- a cryogenic exhaust lumen running substantially the length of the catheter and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the catheter may permit a cryogenic material to flow towards the proximal end of the catheter.
- a junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens.
- the cryogenic material may be prevented from exiting the catheter by a partition distal to the junction isolating the intake lumen and exhaust lumen from the remaining distal portions of the catheter.
- a cryogenic material may be flowed through the catheter by first flowing through an intake lumen and towards the distal end of the catheter. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the catheter, the cryogenic material then flows through the exhaust lumen and back towards the proximal end of the catheter.
- Cryogenic ablation may also be enabled by flowing a cryogenic material through the guide wire.
- lumens running substantially the length of the guide wire and joined by a junction may enable a cryogenic material to flow through the guide wire.
- Such lumens may comprise cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the wire, through which a cryogenic material flows from the proximal end of the guide wire towards its distal end.
- a cryogenic exhaust lumen running substantially the length of the wire and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the wire may permit a cryogenic material to flow towards the proximal end of the wire.
- a junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens.
- the junction connecting the lumens may comprise a chamber internal to the ablation probe into which the intake lumen and exhaust lumen open.
- a cryogenic material may be flowed through the guide wire by first flowing through an intake lumen and towards the distal end of the wire. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the wire, the cryogenic material then flows through the exhaust lumen and back towards the distal end of the catheter.
- the ablative apparatus enables the surgical treatment of cardiac arrhythmias by providing a means to mechanically, ultrasonically, and/or cryogenically ablate myocardial tissue.
- a surgeon utilizing the disclosed ablative apparatus will be able to select the appropriate ablative means or combination of ablative means best suited for the patient's particular pathology and the type of lesion the surgeon wishes to induce.
- Driving the ablation probe with ultrasound energy generated by the transducer enables a surgeon to quickly induce surface abrasions of various depths by adjusting the pulse frequency and duration of the driving ultrasound. This may prove advantageous when the surgeon wishes to induce a lesion at a specific location with minimal collateral injury, such as during AV nodal modification.
- the ablative apparatus may enable the surgeon to cryoablate tissue without the ablation probe adhering to the tissue being ablated. As such, the surgeon may be able to easily move the probe during ablation.
- the ablation probe may be moved during the induction of a lesion by including control means for steering and/or rotating the ablation probe within the handle.
- the probe's mobility during cryoablation could allow the surgeon to create linear lesions in cardiac tissue or isolating lesions in vessel walls.
- the ablative apparatus may give the surgeon greater control over the lesion induced. Furthermore, it has been hypothesized that the administration of low frequency ultrasound and cryoablation induces the release of several healing factors from the targeted tissue.
- ultrasonically vibrating the ablation probe during cryoablation may improve mobility of the ablation probe and possibly induce healing.
- dually administering ultrasonic energy and cryogenic energy may protect surface tissue during the administration of a deep lesion, thereby limiting collateral damage.
- the co-administration of ultrasonic energy will warm the surface tissue preventing it from freezing.
- administering cryogenic energy during the induction of a deep lesion with ultrasonic energy will cool surface tissue thereby protecting it from ablative cavitation, possibly by reducing molecular movement.
- the ablative apparatus may also enable the surgeon to deliver various drugs and/or other pharmacological compounds to the location
- Combining drug delivery with the application of ultrasound energy may assist drug delivery and drug penetration into the targeted tissue.
- Delivering an antithrombolytic during the induction of a lesion may reduce the likelihood of clot formation, especially during mechanical ablation.
- the surgeon may also choose to expedite healing by delivering various healing and/or growth factors to the site of the lesion.
- Drug delivery may be accomplished by coating the ablation probe with a drug or other pharmacological compound. When so coated, driving the ablation probe with ultrasonic energy may liberate the drug coating from the probe and embed it within the targeted tissue.
- the catheter may contain a drug lumen and/or reservoir permitting the administration of a drug to internal locations of the patient's body.
- Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
- Figure 3 depicts an alternative embodiment of the ablative apparatus.
- Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
- Figures 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, a radial surface extending between the
- Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
- ablative apparatus that may be used to treat atrial fibrillation and other arrhythmias. Perferred embodiments of the ablative apparatus are illustrated in the figures and described in detail below. Figure 1 depicts a possible embodiment of the ablative apparatus.
- the ablative apparatus comprises an ablation probe 101, a transducer 102 capable of capable of ultrasonically driving the ablation probe 101 in contact with the proximal surface 103 of ablation probe 101, a guide wire 104 secured at one end to transducer 102, electrical leads 105 running along guide wire 104 and connected to electrodes 113 capable of exposing piezo ceramic disc 112 within transducer 102 to an alternating voltage, a catheter 106 encasing ablation probe 101, transducer 102, and at least a portion of guide wire 104, and a handle 107 secured to the end of guide wire 104 opposite transducer 102.
- catheter 106 is composed of a biologically compatible polymer.
- Handle 107 may contain control means 108 for steering and/or rotating ablation probe 101. Exemplar control means have been described in U.S. Patent Nos. 4,582, 181 and 4,960, 134, the teachings of which are incorporated herein by reference.
- handle 108 may provide a means of rotating ablation probe 101. When rotated, ablation probe 101 moves in a circular motion similar to the manner in which the hands
- Rotation of ablation probe 101 can be accomplished by the surgeon turning handle 107 with his wrist as if he were using a screw driver.
- Guide wire 104 may also carry electrical leads 105 down catheter 106 to transducer 101. Transmitting an electrical current generated by generator 108 to transducer 102, electrical leads 105 energize transducer 102 as to drive ablation probe 101.
- Ablation probe 101 comprises a distal surface 109, a proximal surface 103 opposite the distal surface 109, at least one radial surface 110 extending between distal surface 109 and proximal surface 103, and abrasive members 111 on radial surface 110.
- Transducer 102 in contact with the proximal surface 103 of ablation probe 101, comprises a stack of piezo ceramic discs 112 arranged in a manner similar to that of a roll of coins.
- piezo ceramic discs 112 Running from generator 108 to electrodes 113, electrical leads 105 carry a current to electrodes 113 as to expose piezo ceramic discs 112 to an alternating voltage. So energizing transducer 102 induces the expansion and contraction of piezo ceramic discs 112, as to drive ablation probe 101. Expanding and contracting, piezo ceramic discs 112 apply ultrasonic energy to ablation probe 101. Applying ultrasonic energy to probe 101 may induce a vibrating or oscillating movement of probe 101. As ablation probe 101 moves, abrasive members 111 scratch tissues with which the members 111 contact, as to create an abrasion in the tissue. Back drive 114, located at the proximal end of transducer 102, stabilizes ablation probe 101 when it is driven by ultrasound energy generated by transducer 102.
- catheter 106 encasing ablation probe 101, transducer 102, and a portion of guide wire 104, contains a pocket 115 at its distal end 122 encasing ablation probe 101.
- Encasing ablation probe 101 within pocket 115 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 111 damaging tissue.
- ablation probe 101 may be removed from pocket 115, as to expose abrasive members 111, by firmly pulling catheter 106 towards handle 107.
- sealed tip 116 may contain single or multiple slits 117. Slit(s) 117 may completely or partially penetrate sealed tip 116.
- firmly pulling handle 107 away from the patient while catheter 106 is held stationary returns ablation probe 101 to the inside of pocket 115.
- Advancing the ablative apparatus into and through the patient's body with ablation probe 101 retracted within pocket 115 protects the patient's internal tissues from damage by abrasive members 111.
- the surgeon may retract catheter 106, exposing ablation probe 101.
- the surgeon may then mechanically ablate the target tissue by driving ablation probe 101 with ultrasound energy generated by transducer 102.
- the surgeon may not expose ablation probe 101, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
- flowing a cryogenic material through catheter 106 as to deliver cryogenic energy to ablation probe 101, to a region of catheter 106 in close proximity to ablation probe 101, and/or to another region of catheter 106, may enable cryoablation.
- a cryogenic material may be delivered to catheter 106 from a cryogenic
- cryogenic intake lumen 119 Originating at the proximal end 121 of catheter 106 and running substantially the length of catheter 106, cryogenic intake lumen 119 permits a cryogenic material entering catheter 106 from storage and retrieval unit 118 to flow towards the distal end 122 of catheter 106. After reaching the distal end of intake lumen 119, the cryogenic material flows through a junction connecting intake lumen 119 with exhaust lumen 123 located at the distal end of the intake lumen 119 and exhaust lumen 123.
- the specific junction depicted in Figure 1 comprises a port 124 between intake lumen 119 and exhaust lumen 123.
- exhaust lumen 123 permits the cryogenic material to flow towards proximal end 121 of catheter 106.
- the cryogenic material is returned to storage and retrieval unit 118 via cryogenic exhaust tubing 125 attached to the proximal end exhaust lumen 123, which is in fluid communication with storage and retrieval unit 118 and exhaust lumen 123.
- Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units.
- the storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
- a partition 126 distal to port 124 isolates intake lumen 119 and exhaust lumen 123 from pocket 115.
- catheter 106 In order to prevent catheter 106 from becoming rigid and inflexible as cryogenic material flows through it, catheter 106, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 106, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 104.
- FIGS. 1A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
- Figure 2 A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 extended from pocket 115.
- Figure 2B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 retracted into pocket 115.
- catheter 106 comprises a cryogenic intake lumen 119 and an exhaust lumen 123 (obscured in the present view by intake lumen 119) connected by ports 124.
- the flow of a cryogenic material from the proximal end 121 of catheter 106 towards the distal end 122 of catheter 106 through intake lumen 119, across ports 124, and then back towards the proximal end 122 through exhaust lumen 123 cools pocket 115.
- the cryogenic material flowing through the catheter may also cool ablation probe 101 and/or transducer 102. It should be
- the junction between the intake lumen 119 and exhaust lumen 123 may comprise a chamber.
- FIG. 3 depicts an alternative embodiment of the ablative apparatus.
- the depicted embodiment of the ablative apparatus comprises an ablation probe 301, a transducer 302 capable of ultrasonically driving the ablation probe 301 in contact with the proximal surface 303 of ablation probe 301, a guide wire 304 secured at one end to ablation probe 301 and/or transducer 302, electrical leads 305 running along guide wire 304 and connected to electrodes 313 capable exposing piezo ceramic disc 312 within transducer 302 to an alternating voltage, a catheter 306 encasing ablation probe 301, transducer 302, and at least a portion of guide wire 304, and a handle 307 secured to the end of guide wire 304 opposite ablation probe 301.
- Handle 307 may contain control means 308 for steering and/or rotating ablation probe 301. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which were previously incorporated herein by reference.
- handle 308 may provide a means of rotating ablation probe 301. As with the embodiment depicted in Figure 1, the rotation of ablation probe 301 can be accomplished by the surgeon turning handle 307 with his wrist as if he were using a screw driver.
- guide wire 304 Extending from handle 307, through catheter 306, to ablation probe 301, guide wire 304 provides rigidity to catheter 306. Guide wire 304 may also carry electrical leads 305 down catheter 306 to transducer 302. Transmitting an electrical current generated by generator 308 to transducer 302, electrical leads 305 energize transducer 302 as to drive ablation probe 301.
- Ablation probe 301 comprises a distal surface 309, a proximal surface 303 opposite the distal surface 309, at least one radial surface 310 extending between distal surface 309 and proximal surface 303, and abrasive members 311 on radial surface 310.
- Transducer 302 in contact with the proximal surface 303 of ablation probe 301 and encircling guide wire 304, comprises a stack of piezo ceramic discs 312 arranged in a manner similar to that of a roll of coins.
- catheter 306, encasing ablation probe 301, transducer 302, and a portion of guide wire 304, contains a pocket 315 at its distal end 322 encasing ablation probe 301.
- Encasing ablation probe 301 within pocket 315 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 311 damaging tissue.
- ablation probe 301 may be removed from pocket 315, as
- sealed tip 316 may contain single or multiple slits 317. Slit(s) 317 may completely or partially penetrate sealed tip 316.
- firmly pulling handle 307 away from the patient while holding catheter 306 stationary returns ablation probe 301 to the inside of pocket 315. Advancing the ablative apparatus into and through the patient's body with ablation probe 301 retracted within pocket 315 protects the patient's internal tissues from damage by abrasive members 311.
- the surgeon may retract catheter 306, exposing ablation probe 301.
- the surgeon may then mechanically ablate the target tissue by driving ablation probe 301 with ultrasound energy generated by transducer 302.
- the surgeon may not expose ablation probe 301, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
- cryogenic material may be delivered to guide wire 304 from a cryogenic storage and retrieval unit 318 in fluid communication with cryogenic intake lumen 319 via cryogenic feed tubing 320, attached to the proximal end intake lumen 319. Originating at the proximal end 321 of guide wire 304 and running substantially the length of guide wire 304, cryogenic intake lumen 319 permits a cryogenic material entering guide wire 304 from storage and retrieval unit 318 to flow towards the distal end 326 of guide wire 304. After reaching the distal end of intake lumen 319, the cryogenic material flows through a junction connecting intake lumen 319 with exhaust lumen 323 at the distal end of the intake lumen
- the specific junction depicted in Figure 3 comprises an expansion chamber 324 within ablation probe 301 into which intake tumen 319 and exhaust lumen 323 open.
- the cryogenic material is returned to storage and retrieval unit 318 via cryogenic exhaust tubing 325 attached to the proximal end exhaust lumen 323, which is in fluid communication with storage and retrieval unit 318 and exhaust lumen 323.
- Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units.
- the storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
- catheter 306 In order to prevent catheter 306 from becoming rigid and inflexible as cryogenic material flows through guide wire 304, catheter 306, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 306, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 304.
- Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
- Figure 4 A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 extended from pocket 315.
- Figure 4B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 retracted into pocket 315.
- guide wire 304 comprises
- the junction between the intake lumen 319 and exhaust lumen 323 may comprise one or a series of ports connecting intake lumen 319 with exhaust lumen 323.
- Incorporating threading on a portion of the ablation probe and/or transducer along with corresponding threading on the internal surface of the catheter's pocket may facilitate a smooth deployment of the ablation probe from the catheter's pocket.
- the surgeon would advance the ablation probe from the pocket by rotating the guide wire and attached ablation probe. Rotating the guide wire in the opposite direction would retract the ablation probe back into the pocket.
- the ablation probe of the ablative apparatus may contain one or multiple abrasive members attached to its proximal and/or radial surfaces.
- the abrasive members may be constructed in various configurations, as depicted in Figure 5.
- Figure 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, and a radial surface extending between the proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface.
- the ablation probe 501 depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw.
- the ablation probe 501 depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw.
- the ablation probe 501 depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw.
- abrasive members comprising a thin band 505 attached to radial surface 506 and encircling ablation probe 504.
- ablation probe 507 depicted in Figure 5C
- the abrasive member it also possible for the abrasive member to comprise small particle 508, conceptually similar to a grain of grit on a piece of sand paper, attached to the proximal surface 509 and/or radial surface 510 of ablation probe 507.
- the abrasive member may comprise a protrusion 512 extending from a surface of the ablation probe 511 other than proximal surface 513.
- the ablation probes depicted in Figures 5A-5D may be constructed by attaching or affixing the depicted abrasive members to their proximal and/or radial surfaces.
- the ablation probes depicted in Figures 5A-5D may be constructed such that the abrasive members are extensions of or integral with the ablation probes.
- Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
- the transducer may be comprised of a single piezo ceramic disc.
- the transducer may contain a collection of piezo ceramic discs as depicted in Figure 6.
- the transducer may contain a collection cylindrical piezo ceramic discs 601 stacked upon one another in a manner resembling a roll of coins, as depicted in Figure 6A.
- Such an arrangement may impart an axial or longitudinal displacement upon the driven ablation probe when the transducer is energized.
- the transducer may contain a pair of half cylindrical piezo ceramic discs 602 combined to form a cylinder, as depicted in Figure 6C. Such an arrangement may impart a circumferential displacement upon the driven ablation probe when the transducer is energized.
- the transducer may also contain a
- Such a combination arrangement may impart an axial and circumferential displacement upon the driven ablation probe when the transducer is energized.
- the ultrasound transducer responsible for driving the ablation probe need not be in direct contact with the ablation probe. Instead, the transducer may be in communication with the guide wire attached to the ablation probe, driving the ablation probe through said communication.
- the transducer may be located anywhere within the ablative apparatus, including, but not limited to, the handle. The transducer may also be located elsewhere within the ablative apparatus, provided the transducer is in direct or indirect communication with the ablation probe.
- the transducer utilized in the ablative apparatus should be capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
- the recommended frequency of vibration is approximately 30 kHz to approximately 40 kHz.
- the transducer should also be capable of driving the transducer with ultrasonic energy having an intensity of at least approximately 0.1 Watts per centimeter squared.
- Pulse duration and treatment time are dependent upon the depth and type of lesion the surgeon wishes to induce. Pulsing the ultrasound energy driving the transducer by repeatedly turning the transducer on and off gives the surgeon control over lesion depth. Incorporating an ultrasound controller may permit the surgeon to control, regulate, or adjust, the pulse duration and pulse frequency of the driving ultrasound. Adjusting the
- the surgeon may retract the catheter as to expose the ablation probe's abrasive member(s).
- the surgeon may then mechanical induce an abrasion by driving the ablation probe with ultrasound energy generated by the transducer.
- the surgeon may not expose the ablation probe's abrasive members but rather activate the flow of cryogenic material through the ablative apparatus as to induce a lesion by means of cryoablation. If the surgeon wishes to induce a continuous lesion across a segment of cardiac tissue, the surgeon may activate the transducer as to prevent cryoadhesion of the catheter's distal end to the target tissue.
- Activating the transducer during cryoablation enables the surgeon to warm surface tissue at the site of ablation, thereby protecting surface tissue from ablation or injury.
- activating the flow of cryogenic material through the apparatus while ultrasonically inducing a lesion enables the surgeon to cool surface tissue at the site of the ablation, thereby protecting it from ablation or injury.
- mapping electrode placed at or near the distal end of the ablative apparatus may assist the surgeon in locating specific sites of arrhythmia.
- the mapping electrode may be located at or attached to the ablation probe.
- a mapping electrode may enable the surgeon to detect the electrical activity of the cells near the electrode. The surgeon could use the detected electrical activity to determine if the cells near the electrode are contributing to the arrhythmia.
- the surgeon may administer cryogenic energy to a region of myocardium suspected to be contributing to the patient's arrhythmia as to paralyze the tissue. If paralyzing the tissue completely or
- the surgeon may then ablate the tissue with the ablation probe.
- Incorporating a temperature sensor placed at or near the distal end of the ablative apparatus may enable the surgeon to monitor the temperature at the site of the ablation.
- the sensor may be located near or attached to the ablation probe.
- Monitoring the temperature near or at the site of the ablation with the temperature sensor may assist the surgeon in avoiding burning and/or inflicting other undesirable damage or injury.
- the surgeon could stop the ablation and allow the tissue to return to a safer temperature.
- the surgeon may also adjust the ultrasound parameters as to slow the change in temperature. If the ablative procedure being performed involves the administration of cryogenic energy, the surgeon may adjust the flow of the cryogenic material through the catheter system as to slow the change in temperature.
- the ablative apparatus may also contain a drug lumen through which a drug solution or other fluid or composition may be introduced into the patient's body.
- Ultrasonically driving the ablation probe while simultaneously delivering drug through the apparatus by way of the drug lumen, may be utilized by the surgeon to facilitate the release of the drug from the apparatus, as well as the penetration of the drug into targeted tissue.
- the ablative apparatus may also contain a drug reservoir at its distal end.
- the drug reservoir may surround the ablation probe.
- the drug reservoir may be located proximal to the ablation probe.
- the drug reservoir may contain slits at its base. The slits may completely or partially
- the ablation probe may be coated with a drug. Suspending the drug within a viscous or gel solution may offer better coating of the ablation probe as it travels through the drug reservoir.
- Ultrasonically driving the ablation probe will cause the drug solution clinging to the ablation probe to be liberated from the ablation probe and embedded in the tissue at and surrounding the site of the lesion.
- ultrasonically driving the ablation probe while the probe is retracted may cause the release of drug from the drug reservoir.
- drug delivery during the induction of lesions may be accomplished by first coating the ablation probe with a pharmacological compound. As in the above mention embodiment, ultrasonically driving the ablation probe will liberate the drug coating compound; dispersing it into the targeted tissue.
- biologically compatible polymer refers to polymers, or plastics, that will not normally irritate or harm the body. Such polymers are familiar to those skilled in the art.
- piezo ceramic disc refers to an element composed of a ceramic material expands and contracts when exposed to an alternating voltage. Such ceramics are well known to those skilled in the art. It should be appreciated that “energizing the transducer,” as used herein, refers to inducing the contraction and expansion of piezo ceramic discs within the transducer by exposing the discs to an alternating voltage, as to induce the generation of ultrasonic energy.
- the term "ultrasonically driven,” as used herein, refers to causing the ablation probe to move by applying to the probe ultrasonic energy generated by a transducer in direct or indirect contract with the probe.
- the induced movement of the probe may include vibrating, oscillating, and/or other manners of motion.
- pulse duration refers to the length of time the transducer is generating ultrasonic energy.
- pulse frequency refers to how often ultrasound transducer generates ultrasound during a period of time.
- mechanical ablation refers to injuring a tissue by scratching the tissue as to create an abrasion in the tissue.
- surgeon references all potential users of the disclosed ablative apparatus and does not limit the user of the apparatus to any particular healthcare or medical professional or healthcare or medical professionals in general.
- the disclosed ablative apparatus enables the surgical treatment of atrial fibrillation and/or other arrhythmias.
Abstract
An ablative apparatus that can be used to treat atrial fibrillation and other cardiac arrhythmias by ablating cardiac tissue is disclosed. When the distal end of the apparatus reaches the tissue to be ablated, an ablation probe driven by a transducer vibrates. Scratching the tissue with abrasive members, the vibrating ablation probe is capable of mechanically ablating tissues. This mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The ablative apparatus may then be used subject the exposed myocardium to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
Description
ABLATIVE CARDIAC CATHETER SYSTEM
TECHNICAL FIELD
The present invention relates to an ablative apparatus that can be used to treat atrial fibrillation and/or other cardiac arrhythmias by ablating cardiac tissue.
BACKGROUND ART
Accounting for one-third of the hospitalizations for cardiac arrhythmia, atrial fibrillation (AF) is the most common arrhythmia (abnormal beating of the heart) encountered in clinical practice. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) AF is a specific type of arrhythmia in which an abnormal beating of the heart originates in one of the heart's two atrium. Increasing in prevalence, an estimated 2.2 million Americans suffer from AF. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) Underlying one out of every six strokes, AF doubles the rate of morbidity compared to patients with normal sinus rhythm. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) Further increasing the clinical severity, the presence of AF leads to functional and structural changes in the artial myocardium (cells responsible for the beating of the heart) that favors its maintenance. As such, AF is a serious disorder requiring medical intervention.
Administering drugs that alter the electrical properties of atrial myocardium has been effective in treating less severe cases of AF. (Hurst's the heart, page 836)
However, such drugs often lead to the creation of pro-arrhythmic conditions thereby
resulting in the treatment of one type of arrhythmia only to create another. Due to the increased risk of stroke, it is advised that all patients with AF, despite the successfulness of drug therapy, be prescribed warfarin or other anticoagulants to inhibit the formation of blood clots. (Hurst's the heart, page 833) Besides being difficult to dose, warfarin has
several complications associated with its long term use. Altering the metabolism of other drugs, warfarin is known to induce several adverse interactions with other medications commonly prescribed to elderly patients, who are at increased risk of developing AF.
AF originates in regions of myocardium contracting, or beating, out of step with the rest of the heart. Heart cells contract in response to electrical stimulation. In a healthy heart, the electrical stimulation signaling a contraction originates from the sinus node (the heart's natural pace maker) and spreads in an organized manner across the heart. In a heart plagued with AF, a region of myocardium elicits a mistimed contraction, or heart beat, on its own or in response to an electrical signal generated from somewhere other than the sinus node. Generating an electrical signal, the mistimed contraction spreads across the heart, inducing contractions in neighboring regions of the heart. Inducing the formation of scar tissue on the heart by ablating, cutting, or otherwise injuring tissue in regions in which AF originates has been shown to be affective in treating AF. The logic behind this treatment is to terminate AF by removing the heart cells responsible for its presence, while preserving healthy cells. Creating scar tissue barriers as to prevent the spread of electrical signals from mistimed contractions has also been shown to be effective in treating AF. (Hurst's the heart, page 838)
Successful surgical intervention eliminates the need for continued warfarin treatment in most patients. (Hurst's the heart, page 839) Initially, surgical treatment was
reserved for patients undergoing additional cardiac surgery, such as valve repair or replacement. (Hurst's the heart, page 838) The high success rate and efficacy of
surgical intervention in the treatment of AF has spurred the development of cardiac catheters capable of therapeutically ablating cardiac tissue without the need for open chest or open heart surgery.
Heart surgery performed by means of catheter involves, in its basic conception, the insertion of a catheter either into a patient's vein or chest cavity. The catheter is then advanced to the heart. When the catheter is inserted into a patient's vein, the catheter is advanced into one of the heart's four chambers. When the catheter in inserted into a patient's chest, the catheter is advanced to the outer walls of the patient's heart. After the catheter reaches the patient's heart the surgeon utilizes the catheter to ablate, damage or, kill cardiac tissue. The ideal catheter induced lesion is one that is created from the epicardium (outside) of the beating heart, is able to go through epicardial fat, is performed rapidly over variable lengths, is transmural, causes no collateral injury, and can be applied at any desired anatomic location. (Williams et al., 2004) Ablating cardiac tissue by heating the tissue to 50 degrees Celsius has become the preferred means of inducing lesions (Williams et al., 2004). Cardiac catheters employing a variety of thermal ablative energy sources have been developed, none of which are capable of inducing an ideal lesion.
Catheters utilizing radio frequency as an ablative energy source, the current gold standard, are incapable of creating an ideal lesion. (Cummings et al., 2005) In particular,
radio frequency catheters have a difficult time creating ablations through the epicardial fat surrounding the heart. Furthermore, inducing deep lesions with radio frequency is not possible without inflicting collateral damage resulting from surface burning and steam popping. (Cummings et al., 2005) Steam popping is the phenomenon in which cells become heated to such a point that their internal fluids begin to boil, producing steam that bursts the cell. Simultaneously cooling the site of radio frequency administration reduces the incidence of surface burns but does not reduce the risk of steam popping. (Cummings et al., 2005) In an effort to overcome the shortcomings of radio frequency induced lesions, catheters employing novel energy sources have been developed. In hopes that microwaves would provide sufficiently deep lesions, catheters employing microwaves as an ablative energy source have been developed. Because the penetration of microwaves into tissue has a steep exponential decline, it has been found necessary to bring the catheter into close contact with the tissue in order to induce deep lesions. (Cummings et al., 2005) Furthermore, the exponential decline in energy with tissue depth requires exposing the tissue to high levels of energy when inducing deep lesions. Consequently, surface burning and steam popping is likely during the induction of deep lesions with a microwave catheter. Furthermore, fat continues to be a significant barrier. (Williams et al., 2004)
Lasers have also been applied as an ablative energy source within catheters. Although high powered lasers carry a high risk of crater formation at the site of application, low energy lasers produce lesions with a depth related to the duration of application. (Cummings et al., 2005) Therefore, the ideal rapid induction of a deep
lesion is not possible with laser catheters without the risk of crater formation and collateral damage.
Capable of penetrating fat and inducing a fast lesion at a specific depth when focused, high intensity ultrasound has been predicted to be an advantageous source of ablative energy in catheters. (Williams et al., 2004) However, properly focusing ultrasound energy requires exact knowledge as to the depth of the lesion and the position of the catheter, which may not be possible in a closed heart or closed chest procedure. Furthermore, high intensity ultrasound is capable of inducing internal cavitations resulting in apoptosis (a delayed form of cellular death) as it passes through cells on its way to the desired location of the lesion. Consequently, ultrasound induced lesions, though fast, are not free from the complications of collateral damage. Furthermore, collateral damage may not become apparent until sometime after the procedure.
Besides the specific complications mentioned for the currently available ablative heat energy sources they, as a whole, suffer from shared problems of heat sink and clot formation. With respect to clot formation, the heat produced at the site of energy released from the catheter can result in the formation of blood clots on the catheter. If such blood clots dislodge when the catheter is withdrawn, especially when the catheter is used to induce lesion from within the heart, it can result in serious complications including stroke. The other shared shortcoming, heat sink, can exacerbate the occurrence of clot formation. The continuous blood flow through and around the heart creates a natural heat sink cooling the site of energy application as well as the location of the desired lesion. Consequently, more energy must be emitted from the catheter to heat the
target myocardium to 50 degrees Celsius. Making the catheter hotter, unfortunately, increases the risk of clot formation on and around the catheter.
An alternative to ablation by heating is the practice of ablating tissue by freezing. Severe cold, also know as cryogenic energy, as an ablative energy source has the advantages of avoiding clot formation. (Williams et al., 2004) Another advantage of catheters employing cryogenic energy is the ability to temporarily paralyze regions of myocardium tissue as to test the benefit of a planned lesion. When a region of tissue is paralyzed by freezing, it can no longer initiate an arrhythmia. If paralyzing a region of the heart completely or partially restores a normal heart beat, the surgeon knows she has her catheter aimed at the right spot. However, cryoablative catheters are not without their limitations. In particular, cyroadhesion (the freezing of the catheter to cardiac tissue) though capable of stabilizing the catheter makes it difficult for the surgeon to move the catheter during the ablative procedure. Furthermore, requiring multiple applications for the induction of a therapeutic lesion, cryoablative catheters are not capable of rapidly inducing lesions.
DISCLOSURE OF THE INVENTION
An ablative apparatus that can be used to ablate cardiac tissue is disclosed. The ablative apparatus comprises an ablation probe, a transducer capable of ultrasonically driving the ablation probe in contact with the proximal end of the ablation probe, a guide wire secured at one end to the transducer and/or ablation probe, electrical leads running along the guide wire and connected to electrodes capable of exposing piezo ceramic discs within the transducer to an alternating voltage, a catheter encasing the ablation probe,
transducer, and at least a portion of the guide wire, and a handle secured to the end of the guide wire opposite the transducer. Preferably, the catheter is composed of a biologically compatible polymer.
The ablation probe located at the distal end of the catheter system may comprise a proximal surface, a distal surface opposite the proximal surface, at least one radial surface extending between the proximal surface and the distal surface, and at least one abrasive member on at least one surface other than the proximal surface. As the distal end of the ablative apparatus is advanced towards the heart, the ablation probe may be contained within a pocket at the distal end of the catheter. When the distal end of the catheter reaches the tissue to be ablated, the ablation probe may be removed from the pocket, as to expose the abrasive member(s). When the transducer in contact with the proximal surface of the ablation probe is activated by supplying it with an electrical current, the ablation probe becomes driven by ultrasonic energy generated by the transducer and begins to vibrate. As the ablation probe vibrates, the abrasive members on the ablation probe scratch tissues with which the members come in contact, as to create an abrasion in the tissues. Physically inducing an abrasion within a tissue, the vibrating ablation probe is capable of mechanically ablating tissues. When the ablation probe is advanced to the heart, mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The exposed myocardium may then be subjected to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
Flowing a cryogenic material through the catether, as to deliver cryogenic energy to the ablation probe, to a region of the catheter in close proximity to the ablation probe,
and/or to another region of the catheter, may enable cryoablation. Lumens running substantially the length of the catheter and joined by a junction may enable a cryogenic material to flow through the catheter. Such lumens may comprise a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter, through which a cryogenic material flows from the proximal end of the catheter towards its distal end. Likewise, a cryogenic exhaust lumen running substantially the length of the catheter and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the catheter may permit a cryogenic material to flow towards the proximal end of the catheter. A junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens. The cryogenic material may be prevented from exiting the catheter by a partition distal to the junction isolating the intake lumen and exhaust lumen from the remaining distal portions of the catheter. Thus, a cryogenic material may be flowed through the catheter by first flowing through an intake lumen and towards the distal end of the catheter. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the catheter, the cryogenic material then flows through the exhaust lumen and back towards the proximal end of the catheter.
Cryogenic ablation may also be enabled by flowing a cryogenic material through the guide wire. As with the catheter, lumens running substantially the length of the guide wire and joined by a junction may enable a cryogenic material to flow through the guide wire. Such lumens may comprise cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the wire, through which a
cryogenic material flows from the proximal end of the guide wire towards its distal end. Likewise, a cryogenic exhaust lumen running substantially the length of the wire and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the wire may permit a cryogenic material to flow towards the proximal end of the wire. A junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens. The junction connecting the lumens may comprise a chamber internal to the ablation probe into which the intake lumen and exhaust lumen open. Thus, a cryogenic material may be flowed through the guide wire by first flowing through an intake lumen and towards die distal end of the wire. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the wire, the cryogenic material then flows through the exhaust lumen and back towards the distal end of the catheter.
Regardless of whether a cryogenic material is flowed through the catheter or guide wire, the ablative apparatus enables the surgical treatment of cardiac arrhythmias by providing a means to mechanically, ultrasonically, and/or cryogenically ablate myocardial tissue. As such, a surgeon utilizing the disclosed ablative apparatus will be able to select the appropriate ablative means or combination of ablative means best suited for the patient's particular pathology and the type of lesion the surgeon wishes to induce. Driving the ablation probe with ultrasound energy generated by the transducer enables a surgeon to quickly induce surface abrasions of various depths by adjusting the pulse frequency and duration of the driving ultrasound. This may prove advantageous when
the surgeon wishes to induce a lesion at a specific location with minimal collateral injury, such as during AV nodal modification.
Combining ultrasonic energy with cryogenic energy the ablative apparatus may enable the surgeon to cryoablate tissue without the ablation probe adhering to the tissue being ablated. As such, the surgeon may be able to easily move the probe during ablation. The ablation probe may be moved during the induction of a lesion by including control means for steering and/or rotating the ablation probe within the handle. The probe's mobility during cryoablation could allow the surgeon to create linear lesions in cardiac tissue or isolating lesions in vessel walls. Thus, by combining ultrasonic and cryogenic energy the ablative apparatus may give the surgeon greater control over the lesion induced. Furthermore, it has been hypothesized that the administration of low frequency ultrasound and cryoablation induces the release of several healing factors from the targeted tissue. Therefore, ultrasonically vibrating the ablation probe during cryoablation may improve mobility of the ablation probe and possibly induce healing. Alternatively or in combination, dually administering ultrasonic energy and cryogenic energy may protect surface tissue during the administration of a deep lesion, thereby limiting collateral damage. During the cryogenic induction of a deep lesion, the co-administration of ultrasonic energy will warm the surface tissue preventing it from freezing. Likewise, administering cryogenic energy during the induction of a deep lesion with ultrasonic energy will cool surface tissue thereby protecting it from ablative cavitation, possibly by reducing molecular movement.
In the alternative or in combination, the ablative apparatus may also enable the surgeon to deliver various drugs and/or other pharmacological compounds to the location
of the lesion and/or other locations. Combining drug delivery with the application of ultrasound energy may assist drug delivery and drug penetration into the targeted tissue. Delivering an antithrombolytic during the induction of a lesion may reduce the likelihood of clot formation, especially during mechanical ablation. The surgeon may also choose to expedite healing by delivering various healing and/or growth factors to the site of the lesion.
Drug delivery may be accomplished by coating the ablation probe with a drug or other pharmacological compound. When so coated, driving the ablation probe with ultrasonic energy may liberate the drug coating from the probe and embed it within the targeted tissue. In the alternative or in combination, the catheter may contain a drug lumen and/or reservoir permitting the administration of a drug to internal locations of the patient's body.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 depicts a possible embodiment of the ablative apparatus.
Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
Figure 3 depicts an alternative embodiment of the ablative apparatus. Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
Figures 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, a radial surface extending between the
proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface.
Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
BEST MODE FOR CARRYING OUT THE INVENTION Disclosed is an ablative apparatus that may be used to treat atrial fibrillation and other arrhythmias. Perferred embodiments of the ablative apparatus are illustrated in the figures and described in detail below. Figure 1 depicts a possible embodiment of the ablative apparatus. The ablative apparatus comprises an ablation probe 101, a transducer 102 capable of capable of ultrasonically driving the ablation probe 101 in contact with the proximal surface 103 of ablation probe 101, a guide wire 104 secured at one end to transducer 102, electrical leads 105 running along guide wire 104 and connected to electrodes 113 capable of exposing piezo ceramic disc 112 within transducer 102 to an alternating voltage, a catheter 106 encasing ablation probe 101, transducer 102, and at least a portion of guide wire 104, and a handle 107 secured to the end of guide wire 104 opposite transducer 102. Preferably, catheter 106 is composed of a biologically compatible polymer. Handle 107 may contain control means 108 for steering and/or rotating ablation probe 101. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which are incorporated herein by reference. In addition to housing control means, handle 108 may provide a means of rotating ablation probe 101. When rotated, ablation probe 101 moves in a circular motion similar to the manner in which the hands
of clock move about its face. Rotation of ablation probe 101 can be accomplished by the surgeon turning handle 107 with his wrist as if he were using a screw driver. Extending from handle 107, through catheter 106, to transducer 102, guide wire 104 provides rigidity to catheter 106. Guide wire 104 may also carry electrical leads 105 down catheter 106 to transducer 101. Transmitting an electrical current generated by generator 108 to transducer 102, electrical leads 105 energize transducer 102 as to drive ablation probe 101.
In keeping with Figure 1 , a portion of the distal end 122 of catheter 106 has been cut away as to expose ablation probe 101 and transducer 102. Ablation probe 101 comprises a distal surface 109, a proximal surface 103 opposite the distal surface 109, at least one radial surface 110 extending between distal surface 109 and proximal surface 103, and abrasive members 111 on radial surface 110. Transducer 102, in contact with the proximal surface 103 of ablation probe 101, comprises a stack of piezo ceramic discs 112 arranged in a manner similar to that of a roll of coins. Running from generator 108 to electrodes 113, electrical leads 105 carry a current to electrodes 113 as to expose piezo ceramic discs 112 to an alternating voltage. So energizing transducer 102 induces the expansion and contraction of piezo ceramic discs 112, as to drive ablation probe 101. Expanding and contracting, piezo ceramic discs 112 apply ultrasonic energy to ablation probe 101. Applying ultrasonic energy to probe 101 may induce a vibrating or oscillating movement of probe 101. As ablation probe 101 moves, abrasive members 111 scratch tissues with which the members 111 contact, as to create an abrasion in the tissue. Back drive 114, located at the proximal end of transducer 102, stabilizes ablation probe 101 when it is driven by ultrasound energy generated by transducer 102.
Continuing with Figure 1, catheter 106, encasing ablation probe 101, transducer 102, and a portion of guide wire 104, contains a pocket 115 at its distal end 122 encasing ablation probe 101. Encasing ablation probe 101 within pocket 115 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 111 damaging tissue. When the distal end 122 of the catheter 106 reaches the tissue to be ablated, ablation probe 101 may be removed from pocket 115, as to expose abrasive members 111, by firmly pulling catheter 106 towards handle 107. As to facilitate the penetration of the sealed tip 116 at the distal end of pocket 115 by ablation probe 101, sealed tip 116 may contain single or multiple slits 117. Slit(s) 117 may completely or partially penetrate sealed tip 116. Conversely, firmly pulling handle 107 away from the patient while catheter 106 is held stationary returns ablation probe 101 to the inside of pocket 115. Advancing the ablative apparatus into and through the patient's body with ablation probe 101 retracted within pocket 115 protects the patient's internal tissues from damage by abrasive members 111. When ablation probe 101 has been advanced to the desired location, the surgeon may retract catheter 106, exposing ablation probe 101. The surgeon may then mechanically ablate the target tissue by driving ablation probe 101 with ultrasound energy generated by transducer 102. Alternatively, the surgeon may not expose ablation probe 101, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy. In keeping with Figure 1, flowing a cryogenic material through catheter 106, as to deliver cryogenic energy to ablation probe 101, to a region of catheter 106 in close proximity to ablation probe 101, and/or to another region of catheter 106, may enable cryoablation. A cryogenic material may be delivered to catheter 106 from a cryogenic
storage and retrieval unit b in fluid communication with cryogenic intake lumen 119 via cryogenic feed tubing 120, attached to the proximal end intake lumen 119. Originating at the proximal end 121 of catheter 106 and running substantially the length of catheter 106, cryogenic intake lumen 119 permits a cryogenic material entering catheter 106 from storage and retrieval unit 118 to flow towards the distal end 122 of catheter 106. After reaching the distal end of intake lumen 119, the cryogenic material flows through a junction connecting intake lumen 119 with exhaust lumen 123 located at the distal end of the intake lumen 119 and exhaust lumen 123. The specific junction depicted in Figure 1 comprises a port 124 between intake lumen 119 and exhaust lumen 123. Running substantially the length of catheter 106, substantially parallel to intake lumen 119, and terminating at the proximal end 121 of catheter 106, exhaust lumen 123 permits the cryogenic material to flow towards proximal end 121 of catheter 106. After reaching the proximal end 121 of catheter 106, the cryogenic material is returned to storage and retrieval unit 118 via cryogenic exhaust tubing 125 attached to the proximal end exhaust lumen 123, which is in fluid communication with storage and retrieval unit 118 and exhaust lumen 123. Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units. The storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs. As to prevent the cryogenic material from entering pocket 115 and/or exiting catheter 106, a partition 126 distal to port 124 isolates intake lumen 119 and exhaust lumen 123 from pocket 115.
In order to prevent catheter 106 from becoming rigid and inflexible as cryogenic material flows through it, catheter 106, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 106, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 104.
Disclosed in U.S. Patent Application No. 11/454,018, entitled Method and Apparatus for Treating Vascular Obstructions, and filed July 15, 2006, are exemplar configurations of catheter that may be in the alternative to catheter 106. The teachings of U.S. Patent Application No. 1 1/454,018 are hereby incorporated by reference. Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1. Figure 2A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 extended from pocket 115. Figure 2B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 retracted into pocket 115. As previously stated in the discussion of Figure 1 , catheter 106 comprises a cryogenic intake lumen 119 and an exhaust lumen 123 (obscured in the present view by intake lumen 119) connected by ports 124. The flow of a cryogenic material from the proximal end 121 of catheter 106 towards the distal end 122 of catheter 106 through intake lumen 119, across ports 124, and then back towards the proximal end 122 through exhaust lumen 123 cools pocket 115. Flowing adjacent to or in close proximity to ablation probe 101 and/or transducer 102, the cryogenic material flowing through the catheter may also cool ablation probe 101 and/or transducer 102. It should be
appreciated that in the alternative to the ports depicted in Figures 1 and 2, the junction between the intake lumen 119 and exhaust lumen 123 may comprise a chamber.
Figure 3 depicts an alternative embodiment of the ablative apparatus. The depicted embodiment of the ablative apparatus comprises an ablation probe 301, a transducer 302 capable of ultrasonically driving the ablation probe 301 in contact with the proximal surface 303 of ablation probe 301, a guide wire 304 secured at one end to ablation probe 301 and/or transducer 302, electrical leads 305 running along guide wire 304 and connected to electrodes 313 capable exposing piezo ceramic disc 312 within transducer 302 to an alternating voltage, a catheter 306 encasing ablation probe 301, transducer 302, and at least a portion of guide wire 304, and a handle 307 secured to the end of guide wire 304 opposite ablation probe 301. Handle 307 may contain control means 308 for steering and/or rotating ablation probe 301. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which were previously incorporated herein by reference. In addition to housing control means, handle 308 may provide a means of rotating ablation probe 301. As with the embodiment depicted in Figure 1, the rotation of ablation probe 301 can be accomplished by the surgeon turning handle 307 with his wrist as if he were using a screw driver. Extending from handle 307, through catheter 306, to ablation probe 301, guide wire 304 provides rigidity to catheter 306. Guide wire 304 may also carry electrical leads 305 down catheter 306 to transducer 302. Transmitting an electrical current generated by generator 308 to transducer 302, electrical leads 305 energize transducer 302 as to drive ablation probe 301.
In keeping with Figure 3, a portion of the distal end 322 of catheter 306 has been cut away as to expose ablation probe 301 and transducer 302. Ablation probe 301 comprises a distal surface 309, a proximal surface 303 opposite the distal surface 309, at least one radial surface 310 extending between distal surface 309 and proximal surface 303, and abrasive members 311 on radial surface 310. Transducer 302, in contact with the proximal surface 303 of ablation probe 301 and encircling guide wire 304, comprises a stack of piezo ceramic discs 312 arranged in a manner similar to that of a roll of coins. Running from generator 308 to electrodes 313, electrical leads 305 carry a current to electrodes 313 as to expose piezo ceramic discs 312 to an alternating voltage. So energizing transducer 302 induces the expansion and contraction of piezo ceramic discs 312, as to drive ablation probe 301. Expanding and contracting, piezo ceramic discs 312 apply ultrasonic energy to ablation probe 301. Applying ultrasonic energy to probe 301 may induce a vibrating or oscillating movement of probe 301. As ablation probe 301 moves, abrasive members 311 scratch tissues with which the members 311 come in contact, as to create an abrasion in the tissue. Back drive 314, located at the proximal end of transducer 302, stabilizes ablation probe 301 when it is driven by ultrasound energy generated by transducer 302.
Continuing with Figure 3, catheter 306, encasing ablation probe 301, transducer 302, and a portion of guide wire 304, contains a pocket 315 at its distal end 322 encasing ablation probe 301. Encasing ablation probe 301 within pocket 315 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 311 damaging tissue. When the distal end 322 of the catheter 306 reaches the tissue to be ablated, ablation probe 301 may be removed from pocket 315, as
to expose abrasive members 311, by firmly pulling catheter 306 towards handle 307. As to facilitate the penetration of the sealed tip 316 at the distal end of pocket 315 by ablation probe 301, sealed tip 316 may contain single or multiple slits 317. Slit(s) 317 may completely or partially penetrate sealed tip 316. Conversely, firmly pulling handle 307 away from the patient while holding catheter 306 stationary returns ablation probe 301 to the inside of pocket 315. Advancing the ablative apparatus into and through the patient's body with ablation probe 301 retracted within pocket 315 protects the patient's internal tissues from damage by abrasive members 311. When ablation probe 301 has been advanced to the desired location, the surgeon may retract catheter 306, exposing ablation probe 301. The surgeon may then mechanically ablate the target tissue by driving ablation probe 301 with ultrasound energy generated by transducer 302. Alternatively, the surgeon may not expose ablation probe 301, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
In keeping with Figure 3, flowing a cryogenic material through guide wire 304, as to deliver cryogenic energy to ablation probe 301, may enable cryoablation. A cryogenic material may be delivered to guide wire 304 from a cryogenic storage and retrieval unit 318 in fluid communication with cryogenic intake lumen 319 via cryogenic feed tubing 320, attached to the proximal end intake lumen 319. Originating at the proximal end 321 of guide wire 304 and running substantially the length of guide wire 304, cryogenic intake lumen 319 permits a cryogenic material entering guide wire 304 from storage and retrieval unit 318 to flow towards the distal end 326 of guide wire 304. After reaching the distal end of intake lumen 319, the cryogenic material flows through a junction connecting intake lumen 319 with exhaust lumen 323 at the distal end of the intake lumen
319 and exhaust lumen 323. The specific junction depicted in Figure 3 comprises an expansion chamber 324 within ablation probe 301 into which intake lumen 319 and exhaust lumen 323 open. Running substantially the length of guide wire 304, substantially parallel to intake lumen 319, and terminating at the proximal end 321 of guide wire 304, exhaust lumen 323 permits the cryogenic material to flow towards proximal end 321 of guide wire 304. After reaching the proximal end 321 of guide wire 304, the cryogenic material is returned to storage and retrieval unit 318 via cryogenic exhaust tubing 325 attached to the proximal end exhaust lumen 323, which is in fluid communication with storage and retrieval unit 318 and exhaust lumen 323. Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units. The storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
In order to prevent catheter 306 from becoming rigid and inflexible as cryogenic material flows through guide wire 304, catheter 306, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 306, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 304.
Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3. Figure 4A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 extended from pocket 315. Figure 4B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 retracted into pocket 315. As previously stated in the discussion of Figure 3, guide wire 304 comprises
a cryogenic intake lumen 319 and an exhaust lumen 323 connected by expansion chamber 324. The flow of a cryogenic material from the proximal end 321 of guide wire 304 towards the distal end 326 of guide wire 304 through intake lumen b, across the junction formed by expansion chamber 324, and then back towards the proximal end 322 through exhaust lumen 323 cools ablation probe 301. It should be appreciated that in the alternative to the expansion chamber depicted in Figures 3 and 4, the junction between the intake lumen 319 and exhaust lumen 323 may comprise one or a series of ports connecting intake lumen 319 with exhaust lumen 323.
Incorporating threading on a portion of the ablation probe and/or transducer along with corresponding threading on the internal surface of the catheter's pocket may facilitate a smooth deployment of the ablation probe from the catheter's pocket. In such an embodiment, the surgeon would advance the ablation probe from the pocket by rotating the guide wire and attached ablation probe. Rotating the guide wire in the opposite direction would retract the ablation probe back into the pocket. The ablation probe of the ablative apparatus may contain one or multiple abrasive members attached to its proximal and/or radial surfaces. Furthermore, the abrasive members may be constructed in various configurations, as depicted in Figure 5.
Figure 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, and a radial surface extending between the proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface. The ablation probe 501, depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw. Alternatively, the ablation probe
504, as depicted in Figure 5B, may contain abrasive members comprising a thin band 505 attached to radial surface 506 and encircling ablation probe 504. As indicated by ablation probe 507, depicted in Figure SC, it also possible for the abrasive member to comprise small particle 508, conceptually similar to a grain of grit on a piece of sand paper, attached to the proximal surface 509 and/or radial surface 510 of ablation probe 507. It is also possible, as indicated by ablation probe 511, depicted in Figure 5D, for the abrasive member to comprise a protrusion 512 extending from a surface of the ablation probe 511 other than proximal surface 513. It should be appreciated that the ablation probes depicted in Figures 5A-5D may be constructed by attaching or affixing the depicted abrasive members to their proximal and/or radial surfaces. Alternatively, the ablation probes depicted in Figures 5A-5D may be constructed such that the abrasive members are extensions of or integral with the ablation probes.
Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe. The transducer may be comprised of a single piezo ceramic disc. Alternatively, the transducer may contain a collection of piezo ceramic discs as depicted in Figure 6. For instance, the transducer may contain a collection cylindrical piezo ceramic discs 601 stacked upon one another in a manner resembling a roll of coins, as depicted in Figure 6A. Such an arrangement may impart an axial or longitudinal displacement upon the driven ablation probe when the transducer is energized. Alternatively, the transducer may contain a pair of half cylindrical piezo ceramic discs 602 combined to form a cylinder, as depicted in Figure 6C. Such an arrangement may impart a circumferential displacement upon the driven ablation probe when the transducer is energized. The transducer may also contain a
combination of cylindrical piezo ceramic discs 601 and half cylindrical piezo ceramic discs 602, as depicted in Figure 6B. Such a combination arrangement may impart an axial and circumferential displacement upon the driven ablation probe when the transducer is energized. The ultrasound transducer responsible for driving the ablation probe need not be in direct contact with the ablation probe. Instead, the transducer may be in communication with the guide wire attached to the ablation probe, driving the ablation probe through said communication. In such an embodiment, the transducer may be located anywhere within the ablative apparatus, including, but not limited to, the handle. The transducer may also be located elsewhere within the ablative apparatus, provided the transducer is in direct or indirect communication with the ablation probe.
The transducer utilized in the ablative apparatus should be capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz. The recommended frequency of vibration is approximately 30 kHz to approximately 40 kHz. The transducer should also be capable of driving the transducer with ultrasonic energy having an intensity of at least approximately 0.1 Watts per centimeter squared.
Pulse duration and treatment time are dependent upon the depth and type of lesion the surgeon wishes to induce. Pulsing the ultrasound energy driving the transducer by repeatedly turning the transducer on and off gives the surgeon control over lesion depth. Incorporating an ultrasound controller may permit the surgeon to control, regulate, or adjust, the pulse duration and pulse frequency of the driving ultrasound. Adjusting the
pulse frequency and duration enables the surgeon to control the depth of the lesion inflicted by the ablation probe.
When the ablation probe has been advanced to the desired lesion location, the surgeon may retract the catheter as to expose the ablation probe's abrasive member(s). The surgeon may then mechanical induce an abrasion by driving the ablation probe with ultrasound energy generated by the transducer. Alternatively, the surgeon may not expose the ablation probe's abrasive members but rather activate the flow of cryogenic material through the ablative apparatus as to induce a lesion by means of cryoablation. If the surgeon wishes to induce a continuous lesion across a segment of cardiac tissue, the surgeon may activate the transducer as to prevent cryoadhesion of the catheter's distal end to the target tissue. Activating the transducer during cryoablation enables the surgeon to warm surface tissue at the site of ablation, thereby protecting surface tissue from ablation or injury. Likewise, activating the flow of cryogenic material through the apparatus while ultrasonically inducing a lesion enables the surgeon to cool surface tissue at the site of the ablation, thereby protecting it from ablation or injury.
Incorporating a mapping electrode placed at or near the distal end of the ablative apparatus may assist the surgeon in locating specific sites of arrhythmia. Alternatively, the mapping electrode may be located at or attached to the ablation probe. A mapping electrode may enable the surgeon to detect the electrical activity of the cells near the electrode. The surgeon could use the detected electrical activity to determine if the cells near the electrode are contributing to the arrhythmia. Furthermore, the surgeon may administer cryogenic energy to a region of myocardium suspected to be contributing to the patient's arrhythmia as to paralyze the tissue. If paralyzing the tissue completely or
partially corrects the arrhythmia, the surgeon may then ablate the tissue with the ablation probe.
Incorporating a temperature sensor placed at or near the distal end of the ablative apparatus may enable the surgeon to monitor the temperature at the site of the ablation. Alternatively, the sensor may be located near or attached to the ablation probe.
Monitoring the temperature near or at the site of the ablation with the temperature sensor may assist the surgeon in avoiding burning and/or inflicting other undesirable damage or injury. When the temperature of the tissue being ablated reaches or approaches an undesirable level, the surgeon could stop the ablation and allow the tissue to return to a safer temperature. The surgeon may also adjust the ultrasound parameters as to slow the change in temperature. If the ablative procedure being performed involves die administration of cryogenic energy, the surgeon may adjust the flow of the cryogenic material through the catheter system as to slow the change in temperature.
The ablative apparatus may also contain a drug lumen through which a drug solution or other fluid or composition may be introduced into the patient's body.
Ultrasonically driving the ablation probe, while simultaneously delivering drug through the apparatus by way of the drug lumen, may be utilized by the surgeon to facilitate the release of the drug from the apparatus, as well as the penetration of the drug into targeted tissue. The ablative apparatus may also contain a drug reservoir at its distal end. The drug reservoir may surround the ablation probe. Alternatively, the drug reservoir may be located proximal to the ablation probe. When located proximal to the ablation probe, the drug reservoir may contain slits at its base. The slits may completely or partially
penetrate the base of the drug reservoir. Retracting the catheter may then cause the ablation probe to penetrate the base of the drug reservoir and eventually the distal end of the reservoir. Traveling through the reservoir, the ablation probe may be coated with a drug. Suspending the drug within a viscous or gel solution may offer better coating of the ablation probe as it travels through the drug reservoir. Ultrasonically driving the ablation probe will cause the drug solution clinging to the ablation probe to be liberated from the ablation probe and embedded in the tissue at and surrounding the site of the lesion. Similarly, ultrasonically driving the ablation probe while the probe is retracted may cause the release of drug from the drug reservoir. Alternatively, drug delivery during the induction of lesions may be accomplished by first coating the ablation probe with a pharmacological compound. As in the above mention embodiment, ultrasonically driving the ablation probe will liberate the drug coating compound; dispersing it into the targeted tissue.
It should be appreciated that the term "biologically compatible polymer," as used herein, refers to polymers, or plastics, that will not normally irritate or harm the body. Such polymers are familiar to those skilled in the art. it should be appreciate that term "piezo ceramic disc," as used herein, refers to an element composed of a ceramic material expands and contracts when exposed to an alternating voltage. Such ceramics are well known to those skilled in the art. It should be appreciated that "energizing the transducer," as used herein, refers to inducing the contraction and expansion of piezo ceramic discs within the transducer by exposing the discs to an alternating voltage, as to induce the generation of ultrasonic energy.
It should be appreciated that the term "ultrasonically driven," as used herein, refers to causing the ablation probe to move by applying to the probe ultrasonic energy generated by a transducer in direct or indirect contract with the probe. The induced movement of the probe may include vibrating, oscillating, and/or other manners of motion.
It should be appreciated that the terra "pulse duration," as used herein, refers to the length of time the transducer is generating ultrasonic energy.
It should be appreciated that the term "pulse frequency," as used herein, refers to how often ultrasound transducer generates ultrasound during a period of time. It should be appreciated that the term "mechanical ablation," as used herein, refers to injuring a tissue by scratching the tissue as to create an abrasion in the tissue.
It should be appreciated that the term "surgeon," as used herein, references all potential users of the disclosed ablative apparatus and does not limit the user of the apparatus to any particular healthcare or medical professional or healthcare or medical professionals in general.
Although specific embodiments and methods of use have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that any arrangement that is calculated to achieve the same purpose may be substituted for the specific embodiments and methods shown. It is to be understood that the above description is intended to be illustrative and not restrictive. Combinations of the above embodiments and other embodiments as well as combinations of the above methods of use and other methods of use will be apparent to those having skill in the art upon review of the present disclosure. The scope of the present invention should be determined with
reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
INDUSTRIAL APPLICABILITY The disclosed ablative apparatus enables the surgical treatment of atrial fibrillation and/or other arrhythmias.
ABLATIVE CARDIAC CATHETER SYSTEM
TECHNICAL FIELD
The present invention relates to an ablative apparatus that can be used to treat atrial fibrillation and/or other cardiac arrhythmias by ablating cardiac tissue.
BACKGROUND ART
Accounting for one-third of the hospitalizations for cardiac arrhythmia, atrial fibrillation (AF) is the most common arrhythmia (abnormal beating of the heart) encountered in clinical practice. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) AF is a specific type of arrhythmia in which an abnormal beating of the heart originates in one of the heart's two atrium. Increasing in prevalence, an estimated 2.2 million Americans suffer from AF. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) Underlying one out of every six strokes, AF doubles the rate of morbidity compared to patients with normal sinus rhythm. (ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation) Further increasing the clinical severity, the presence of AF leads to functional and structural changes in the artial myocardium (cells responsible for the beating of the heart) that favors its maintenance. As such, AF is a serious disorder requiring medical intervention.
Administering drugs that alter the electrical properties of atrial myocardium has been effective in treating less severe cases of AF. (Hurst's the heart, page 836)
However, such drugs often lead to the creation of pro-arrhythmic conditions thereby
resulting in the treatment of one type of arrhythmia only to create another. Due to the increased risk of stroke, it is advised that all patients with AF, despite the successfulness of drug therapy, be prescribed warfarin or other anticoagulants to inhibit the formation of blood clots. (Hurst's the heart, page 833) Besides being difficult to dose, warfarin has
several complications associated with its long term use. Altering the metabolism of other drugs, warfarin is known to induce several adverse interactions with other medications commonly prescribed to elderly patients, who are at increased risk of developing AF.
AF originates in regions of myocardium contracting, or beating, out of step with the rest of the heart. Heart cells contract in response to electrical stimulation. In a healthy heart, the electrical stimulation signaling a contraction originates from the sinus node (the heart's natural pace maker) and spreads in an organized manner across the heart. In a heart plagued with AF, a region of myocardium elicits a mistimed contraction, or heart beat, on its own or in response to an electrical signal generated from somewhere other than the sinus node. Generating an electrical signal, the mistimed contraction spreads across the heart, inducing contractions in neighboring regions of the heart. Inducing the formation of scar tissue on the heart by ablating, cutting, or otherwise injuring tissue in regions in which AF originates has been shown to be affective in treating AF. The logic behind this treatment is to terminate AF by removing the heart cells responsible for its presence, while preserving healthy cells. Creating scar tissue barriers as to prevent the spread of electrical signals from mistimed contractions has also been shown to be effective in treating AF. (Hurst's the heart, page 838)
Successful surgical intervention eliminates the need for continued warfarin treatment in most patients. (Hurst's the heart, page 839) Initially, surgical treatment was
reserved for patients undergoing additional cardiac surgery, such as valve repair or replacement. (Hurst's the heart, page 838) The high success rate and efficacy of
surgical intervention in the treatment of AF has spurred the development of cardiac catheters capable of therapeutically ablating cardiac tissue without the need for open chest or open heart surgery.
Heart surgery performed by means of catheter involves, in its basic conception, the insertion of a catheter either into a patient's vein or chest cavity. The catheter is then advanced to the heart. When the catheter is inserted into a patient's vein, the catheter is advanced into one of the heart's four chambers. When the catheter in inserted into a patient's chest, the catheter is advanced to the outer walls of the patient's heart. After the catheter reaches the patient's heart the surgeon utilizes the catheter to ablate, damage or, kill cardiac tissue. The ideal catheter induced lesion is one that is created from the epicardium (outside) of the beating heart, is able to go through epicardial fat, is performed rapidly over variable lengths, is transmural, causes no collateral injury, and can be applied at any desired anatomic location. (Williams et al., 2004) Ablating cardiac tissue by heating the tissue to 50 degrees Celsius has become the preferred means of inducing lesions (Williams et al., 2004). Cardiac catheters employing a variety of thermal ablative energy sources have been developed, none of which are capable of inducing an ideal lesion.
Catheters utilizing radio frequency as an ablative energy source, the current gold standard, are incapable of creating an ideal lesion. (Cummings et al., 2005) In particular,
radio frequency catheters have a difficult time creating ablations through the epicardial fat surrounding the heart. Furthermore, inducing deep lesions with radio frequency is not possible without inflicting collateral damage resulting from surface burning and steam popping. (Cummings et al., 2005) Steam popping is the phenomenon in which cells become heated to such a point that their internal fluids begin to boil, producing steam that bursts the cell. Simultaneously cooling the site of radio frequency administration reduces the incidence of surface burns but does not reduce the risk of steam popping. (Cummings et al., 2005) In an effort to overcome the shortcomings of radio frequency induced lesions, catheters employing novel energy sources have been developed. In hopes that microwaves would provide sufficiently deep lesions, catheters employing microwaves as an ablative energy source have been developed. Because the penetration of microwaves into tissue has a steep exponential decline, it has been found necessary to bring the catheter into close contact with the tissue in order to induce deep lesions. (Cummings et al., 2005) Furthermore, the exponential decline in energy with tissue depth requires exposing the tissue to high levels of energy when inducing deep lesions. Consequently, surface burning and steam popping is likely during the induction of deep lesions with a microwave catheter. Furthermore, fat continues to be a significant barrier. (Williams et al., 2004)
Lasers have also been applied as an ablative energy source within catheters. Although high powered lasers carry a high risk of crater formation at the site of application, low energy lasers produce lesions with a depth related to the duration of application. (Cummings et al., 2005) Therefore, the ideal rapid induction of a deep
lesion is not possible with laser catheters without the risk of crater formation and collateral damage.
Capable of penetrating fat and inducing a fast lesion at a specific depth when focused, high intensity ultrasound has been predicted to be an advantageous source of ablative energy in catheters. (Williams et al., 2004) However, properly focusing ultrasound energy requires exact knowledge as to the depth of the lesion and the position of the catheter, which may not be possible in a closed heart or closed chest procedure. Furthermore, high intensity ultrasound is capable of inducing internal cavitations resulting in apoptosis (a delayed form of cellular death) as it passes through cells on its way to the desired location of the lesion. Consequently, ultrasound induced lesions, though fast, are not free from the complications of collateral damage. Furthermore, collateral damage may not become apparent until sometime after the procedure.
Besides the specific complications mentioned for the currently available ablative heat energy sources they, as a whole, suffer from shared problems of heat sink and clot formation. With respect to clot formation, the heat produced at the site of energy released from the catheter can result in the formation of blood clots on the catheter. If such blood clots dislodge when the catheter is withdrawn, especially when the catheter is used to induce lesion from within the heart, it can result in serious complications including stroke. The other shared shortcoming, heat sink, can exacerbate the occurrence of clot formation. The continuous blood flow through and around the heart creates a natural heat sink cooling the site of energy application as well as the location of the desired lesion. Consequently, more energy must be emitted from the catheter to heat the
target myocardium to 50 degrees Celsius. Making the catheter hotter, unfortunately, increases the risk of clot formation on and around the catheter.
An alternative to ablation by heating is the practice of ablating tissue by freezing. Severe cold, also know as cryogenic energy, as an ablative energy source has the advantages of avoiding clot formation. (Williams et al., 2004) Another advantage of catheters employing cryogenic energy is the ability to temporarily paralyze regions of myocardium tissue as to test the benefit of a planned lesion. When a region of tissue is paralyzed by freezing, it can no longer initiate an arrhythmia. If paralyzing a region of the heart completely or partially restores a normal heart beat, the surgeon knows she has her catheter aimed at the right spot. However, cryoablative catheters are not without their limitations. In particular, cyroadhesion (the freezing of the catheter to cardiac tissue) though capable of stabilizing the catheter makes it difficult for the surgeon to move the catheter during the ablative procedure. Furthermore, requiring multiple applications for the induction of a therapeutic lesion, cryoablative catheters are not capable of rapidly inducing lesions.
DISCLOSURE OF THE INVENTION
An ablative apparatus that can be used to ablate cardiac tissue is disclosed. The ablative apparatus comprises an ablation probe, a transducer capable of ultrasonically driving the ablation probe in contact with the proximal end of the ablation probe, a guide wire secured at one end to the transducer and/or ablation probe, electrical leads running along the guide wire and connected to electrodes capable of exposing piezo ceramic discs within the transducer to an alternating voltage, a catheter encasing the ablation probe,
transducer, and at least a portion of the guide wire, and a handle secured to the end of the guide wire opposite the transducer. Preferably, the catheter is composed of a biologically compatible polymer.
The ablation probe located at the distal end of the catheter system may comprise a proximal surface, a distal surface opposite the proximal surface, at least one radial surface extending between the proximal surface and the distal surface, and at least one abrasive member on at least one surface other than the proximal surface. As the distal end of the ablative apparatus is advanced towards the heart, the ablation probe may be contained within a pocket at the distal end of the catheter. When the distal end of the catheter reaches the tissue to be ablated, the ablation probe may be removed from the pocket, as to expose the abrasive member(s). When the transducer in contact with the proximal surface of the ablation probe is activated by supplying it with an electrical current, the ablation probe becomes driven by ultrasonic energy generated by the transducer and begins to vibrate. As the ablation probe vibrates, the abrasive members on the ablation probe scratch tissues with which the members come in contact, as to create an abrasion in the tissues. Physically inducing an abrasion within a tissue, the vibrating ablation probe is capable of mechanically ablating tissues. When the ablation probe is advanced to the heart, mechanical ablation may be utilized to penetrate epicardial fat, thereby exposing the underlying myocardium. The exposed myocardium may then be subjected to mechanical ablation, cryoablation, ultrasonic ablation, and/or any combination thereof.
Flowing a cryogenic material through the catether, as to deliver cryogenic energy to the ablation probe, to a region of the catheter in close proximity to the ablation probe,
and/or to another region of the catheter, may enable cryoablation. Lumens running substantially the length of the catheter and joined by a junction may enable a cryogenic material to flow through the catheter. Such lumens may comprise a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter, through which a cryogenic material flows from the proximal end of the catheter towards its distal end. Likewise, a cryogenic exhaust lumen running substantially the length of the catheter and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the catheter may permit a cryogenic material to flow towards the proximal end of the catheter. A junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens. The cryogenic material may be prevented from exiting the catheter by a partition distal to the junction isolating the intake lumen and exhaust lumen from the remaining distal portions of the catheter. Thus, a cryogenic material may be flowed through the catheter by first flowing through an intake lumen and towards the distal end of the catheter. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the catheter, the cryogenic material then flows through the exhaust lumen and back towards the proximal end of the catheter.
Cryogenic ablation may also be enabled by flowing a cryogenic material through the guide wire. As with the catheter, lumens running substantially the length of the guide wire and joined by a junction may enable a cryogenic material to flow through the guide wire. Such lumens may comprise cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the wire, through which a
cryogenic material flows from the proximal end of the guide wire towards its distal end. Likewise, a cryogenic exhaust lumen running substantially the length of the wire and substantially parallel to the cryogenic intake lumen and terminating at the proximal end of the wire may permit a cryogenic material to flow towards the proximal end of the wire. A junction at the distal end of the intake lumen and exhaust lumen connecting the lumens may permit a cryogenic material to be exchanged between the lumens. The junction connecting the lumens may comprise a chamber internal to the ablation probe into which the intake lumen and exhaust lumen open. Thus, a cryogenic material may be flowed through the guide wire by first flowing through an intake lumen and towards the distal end of the wire. The cryogenic material then exits the intake lumen and enters the exhaust lumen at a junction connecting the lumens. Completing its flow through the wire, the cryogenic material then flows through the exhaust lumen and back towards the distal end of the catheter.
Regardless of whether a cryogenic material is flowed through the catheter or guide wire, the ablative apparatus enables the surgical treatment of cardiac arrhythmias by providing a means to mechanically, ultrasonically, and/or cryogenically ablate myocardial tissue. As such, a surgeon utilizing the disclosed ablative apparatus will be able to select the appropriate ablative means or combination of ablative means best suited for the patient's particular pathology and the type of lesion the surgeon wishes to induce. Driving the ablation probe with ultrasound energy generated by the transducer enables a surgeon to quickly induce surface abrasions of various depths by adjusting the pulse frequency and duration of the driving ultrasound. This may prove advantageous when
the surgeon wishes to induce a lesion at a specific location with minimal collateral injury, such as during AV nodal modification.
Combining ultrasonic energy with cryogenic energy the ablative apparatus may enable the surgeon to cryoablate tissue without the ablation probe adhering to the tissue being ablated. As such, the surgeon may be able to easily move the probe during ablation. The ablation probe may be moved during the induction of a lesion by including control means for steering and/or rotating the ablation probe within the handle. The probe's mobility during cryoablation could allow the surgeon to create linear lesions in cardiac tissue or isolating lesions in vessel walls. Thus, by combining ultrasonic and cryogenic energy the ablative apparatus may give the surgeon greater control over the lesion induced. Furthermore, it has been hypothesized that the administration of low frequency ultrasound and cryoablation induces the release of several healing factors from the targeted tissue. Therefore, ultrasonically vibrating the ablation probe during cryoablation may improve mobility of the ablation probe and possibly induce healing. Alternatively or in combination, dually administering ultrasonic energy and cryogenic energy may protect surface tissue during the administration of a deep lesion, thereby limiting collateral damage. During the cryogenic induction of a deep lesion, the co-administration of ultrasonic energy will warm the surface tissue preventing it from freezing. Likewise, administering cryogenic energy during the induction of a deep lesion with ultrasonic energy will cool surface tissue thereby protecting it from ablative cavitation, possibly by reducing molecular movement.
In the alternative or in combination, the ablative apparatus may also enable the surgeon to deliver various drugs and/or other pharmacological compounds to the location
10
of the lesion and/or other locations. Combining drug delivery with the application of ultrasound energy may assist drug delivery and drug penetration into the targeted tissue. Delivering an antithrombolytic during the induction of a lesion may reduce the likelihood of clot formation, especially during mechanical ablation. The surgeon may also choose to expedite healing by delivering various healing and/or growth factors to the site of the lesion.
Drug delivery may be accomplished by coating the ablation probe with a drug or other pharmacological compound. When so coated, driving the ablation probe with ultrasonic energy may liberate the drug coating from the probe and embed it within the targeted tissue. In the alternative or in combination, the catheter may contain a drug lumen and/or reservoir permitting the administration of a drug to internal locations of the patient's body.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 depicts a possible embodiment of the ablative apparatus.
Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1.
Figure 3 depicts an alternative embodiment of the ablative apparatus. Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3.
Figures 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, a radial surface extending between the
11
proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface.
Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe.
BEST MODE FOR CARRYING OUT THE INVENTION Disclosed is an ablative apparatus that may be used to treat atrial fibrillation and other arrhythmias. Perferred embodiments of the ablative apparatus are illustrated in the figures and described in detail below. Figure 1 depicts a possible embodiment of the ablative apparatus. The ablative apparatus comprises an ablation probe 101, a transducer 102 capable of capable of ultrasonically driving the ablation probe 101 in contact with the proximal surface 103 of ablation probe 101, a guide wire 104 secured at one end to transducer 102, electrical leads 105 running along guide wire 104 and connected to electrodes 113 capable of exposing piezo ceramic disc 112 within transducer 102 to an alternating voltage, a catheter 106 encasing ablation probe 101, transducer 102, and at least a portion of guide wire 104, and a handle 107 secured to the end of guide wire 104 opposite transducer 102. Preferably, catheter 106 is composed of a biologically compatible polymer. Handle 107 may contain control means 108 for steering and/or rotating ablation probe 101. Exemplar control means have been described in U.S. Patent Nos. 4,582, 181 and 4,960, 134, the teachings of which are incorporated herein by reference. In addition to housing control means, handle 108 may provide a means of rotating ablation probe 101. When rotated, ablation probe 101 moves in a circular motion similar to the manner in which the hands
12
of clock move about its face. Rotation of ablation probe 101 can be accomplished by the surgeon turning handle 107 with his wrist as if he were using a screw driver. Extending from handle 107, through catheter 106, to transducer 102, guide wire 104 provides rigidity to catheter 106. Guide wire 104 may also carry electrical leads 105 down catheter 106 to transducer 101. Transmitting an electrical current generated by generator 108 to transducer 102, electrical leads 105 energize transducer 102 as to drive ablation probe 101.
In keeping with Figure 1 , a portion of the distal end 122 of catheter 106 has been cut away as to expose ablation probe 101 and transducer 102. Ablation probe 101 comprises a distal surface 109, a proximal surface 103 opposite the distal surface 109, at least one radial surface 110 extending between distal surface 109 and proximal surface 103, and abrasive members 111 on radial surface 110. Transducer 102, in contact with the proximal surface 103 of ablation probe 101, comprises a stack of piezo ceramic discs 112 arranged in a manner similar to that of a roll of coins. Running from generator 108 to electrodes 113, electrical leads 105 carry a current to electrodes 113 as to expose piezo ceramic discs 112 to an alternating voltage. So energizing transducer 102 induces the expansion and contraction of piezo ceramic discs 112, as to drive ablation probe 101. Expanding and contracting, piezo ceramic discs 112 apply ultrasonic energy to ablation probe 101. Applying ultrasonic energy to probe 101 may induce a vibrating or oscillating movement of probe 101. As ablation probe 101 moves, abrasive members 111 scratch tissues with which the members 111 contact, as to create an abrasion in the tissue. Back drive 114, located at the proximal end of transducer 102, stabilizes ablation probe 101 when it is driven by ultrasound energy generated by transducer 102.
13
Continuing with Figure 1, catheter 106, encasing ablation probe 101, transducer 102, and a portion of guide wire 104, contains a pocket 115 at its distal end 122 encasing ablation probe 101. Encasing ablation probe 101 within pocket 115 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 111 damaging tissue. When the distal end 122 of the catheter 106 reaches the tissue to be ablated, ablation probe 101 may be removed from pocket 115, as to expose abrasive members 111, by firmly pulling catheter 106 towards handle 107. As to facilitate the penetration of the sealed tip 116 at the distal end of pocket 115 by ablation probe 101, sealed tip 116 may contain single or multiple slits 117. Slit(s) 117 may completely or partially penetrate sealed tip 116. Conversely, firmly pulling handle 107 away from the patient while catheter 106 is held stationary returns ablation probe 101 to the inside of pocket 115. Advancing the ablative apparatus into and through the patient's body with ablation probe 101 retracted within pocket 115 protects the patient's internal tissues from damage by abrasive members 111. When ablation probe 101 has been advanced to the desired location, the surgeon may retract catheter 106, exposing ablation probe 101. The surgeon may then mechanically ablate the target tissue by driving ablation probe 101 with ultrasound energy generated by transducer 102. Alternatively, the surgeon may not expose ablation probe 101, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy. In keeping with Figure 1, flowing a cryogenic material through catheter 106, as to deliver cryogenic energy to ablation probe 101, to a region of catheter 106 in close proximity to ablation probe 101, and/or to another region of catheter 106, may enable cryoablation. A cryogenic material may be delivered to catheter 106 from a cryogenic
14
storage and retrieval unit b in fluid communication with cryogenic intake lumen 119 via cryogenic feed tubing 120, attached to the proximal end intake lumen 119. Originating at the proximal end 121 of catheter 106 and running substantially the length of catheter 106, cryogenic intake lumen 119 permits a cryogenic material entering catheter 106 from storage and retrieval unit 118 to flow towards the distal end 122 of catheter 106. After reaching the distal end of intake lumen 119, the cryogenic material flows through a junction connecting intake lumen 119 with exhaust lumen 123 located at the distal end of the intake lumen 119 and exhaust lumen 123. The specific junction depicted in Figure 1 comprises a port 124 between intake lumen 119 and exhaust lumen 123. Running substantially the length of catheter 106, substantially parallel to intake lumen 119, and terminating at the proximal end 121 of catheter 106, exhaust lumen 123 permits the cryogenic material to flow towards proximal end 121 of catheter 106. After reaching the proximal end 121 of catheter 106, the cryogenic material is returned to storage and retrieval unit 118 via cryogenic exhaust tubing 125 attached to the proximal end exhaust lumen 123, which is in fluid communication with storage and retrieval unit 118 and exhaust lumen 123. Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units. The storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs. As to prevent the cryogenic material from entering pocket 115 and/or exiting catheter 106, a partition 126 distal to port 124 isolates intake lumen 119 and exhaust lumen 123 from pocket 115.
15
In order to prevent catheter 106 from becoming rigid and inflexible as cryogenic material flows through it, catheter 106, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 106, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 104.
Disclosed in U.S. Patent Application No. 11/454,018, entitled Method and Apparatus for Treating Vascular Obstructions, and filed July 15, 2006, are exemplar configurations of catheter that may be in the alternative to catheter 106. The teachings of U.S. Patent Application No. 11/454,018 are hereby incorporated by reference. Figures 2A-2B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 1. Figure 2 A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 extended from pocket 115. Figure 2B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 1 with ablation probe 101 retracted into pocket 115. As previously stated in the discussion of Figure 1, catheter 106 comprises a cryogenic intake lumen 119 and an exhaust lumen 123 (obscured in the present view by intake lumen 119) connected by ports 124. The flow of a cryogenic material from the proximal end 121 of catheter 106 towards the distal end 122 of catheter 106 through intake lumen 119, across ports 124, and then back towards the proximal end 122 through exhaust lumen 123 cools pocket 115. Flowing adjacent to or in close proximity to ablation probe 101 and/or transducer 102, the cryogenic material flowing through the catheter may also cool ablation probe 101 and/or transducer 102. It should be
16
appreciated that in the alternative to the ports depicted in Figures 1 and 2, the junction between the intake lumen 119 and exhaust lumen 123 may comprise a chamber.
Figure 3 depicts an alternative embodiment of the ablative apparatus. The depicted embodiment of the ablative apparatus comprises an ablation probe 301, a transducer 302 capable of ultrasonically driving the ablation probe 301 in contact with the proximal surface 303 of ablation probe 301, a guide wire 304 secured at one end to ablation probe 301 and/or transducer 302, electrical leads 305 running along guide wire 304 and connected to electrodes 313 capable exposing piezo ceramic disc 312 within transducer 302 to an alternating voltage, a catheter 306 encasing ablation probe 301, transducer 302, and at least a portion of guide wire 304, and a handle 307 secured to the end of guide wire 304 opposite ablation probe 301. Handle 307 may contain control means 308 for steering and/or rotating ablation probe 301. Exemplar control means have been described in U.S. Patent Nos. 4,582,181 and 4,960,134, the teachings of which were previously incorporated herein by reference. In addition to housing control means, handle 308 may provide a means of rotating ablation probe 301. As with the embodiment depicted in Figure 1, the rotation of ablation probe 301 can be accomplished by the surgeon turning handle 307 with his wrist as if he were using a screw driver. Extending from handle 307, through catheter 306, to ablation probe 301, guide wire 304 provides rigidity to catheter 306. Guide wire 304 may also carry electrical leads 305 down catheter 306 to transducer 302. Transmitting an electrical current generated by generator 308 to transducer 302, electrical leads 305 energize transducer 302 as to drive ablation probe 301.
17
In keeping with Figure 3, a portion of the distal end 322 of catheter 306 has been cut away as to expose ablation probe 301 and transducer 302. Ablation probe 301 comprises a distal surface 309, a proximal surface 303 opposite the distal surface 309, at least one radial surface 310 extending between distal surface 309 and proximal surface 303, and abrasive members 311 on radial surface 310. Transducer 302, in contact with the proximal surface 303 of ablation probe 301 and encircling guide wire 304, comprises a stack of piezo ceramic discs 312 arranged in a manner similar to that of a roll of coins. Running from generator 308 to electrodes 313, electrical leads 305 carry a current to electrodes 313 as to expose piezo ceramic discs 312 to an alternating voltage. So energizing transducer 302 induces the expansion and contraction of piezo ceramic discs 312, as to drive ablation probe 301. Expanding and contracting, piezo ceramic discs 312 apply ultrasonic energy to ablation probe 301. Applying ultrasonic energy to probe 301 may induce a vibrating or oscillating movement of probe 301. As ablation probe 301 moves, abrasive members 311 scratch tissues with which the members 311 come in contact, as to create an abrasion in the tissue. Back drive 314, located at the proximal end of transducer 302, stabilizes ablation probe 301 when it is driven by ultrasound energy generated by transducer 302.
Continuing with Figure 3, catheter 306, encasing ablation probe 301, transducer 302, and a portion of guide wire 304, contains a pocket 315 at its distal end 322 encasing ablation probe 301. Encasing ablation probe 301 within pocket 315 may enable the distal end of the ablative apparatus to be advanced towards the tissue to be ablated without abrasive members 311 damaging tissue. When the distal end 322 of the catheter 306 reaches the tissue to be ablated, ablation probe 301 may be removed from pocket 315, as
18
to expose abrasive members 311, by firmly pulling catheter 306 towards handle 307. As to facilitate the penetration of the sealed tip 316 at the distal end of pocket 315 by ablation probe 301, sealed tip 316 may contain single or multiple slits 317. Slit(s) 317 may completely or partially penetrate sealed tip 316. Conversely, firmly pulling handle 307 away from the patient while holding catheter 306 stationary returns ablation probe 301 to the inside of pocket 315. Advancing the ablative apparatus into and through the patient's body with ablation probe 301 retracted within pocket 315 protects the patient's internal tissues from damage by abrasive members 311. When ablation probe 301 has been advanced to the desired location, the surgeon may retract catheter 306, exposing ablation probe 301. The surgeon may then mechanically ablate the target tissue by driving ablation probe 301 with ultrasound energy generated by transducer 302. Alternatively, the surgeon may not expose ablation probe 301, but rather induce a lesion with low frequency ultrasound energy and/or cryogenic energy.
In keeping with Figure 3, flowing a cryogenic material through guide wire 304, as to deliver cryogenic energy to ablation probe 301, may enable cryoablation. A cryogenic material may be delivered to guide wire 304 from a cryogenic storage and retrieval unit 318 in fluid communication with cryogenic intake lumen 319 via cryogenic feed tubing 320, attached to the proximal end intake lumen 319. Originating at the proximal end 321 of guide wire 304 and running substantially the length of guide wire 304, cryogenic intake lumen 319 permits a cryogenic material entering guide wire 304 from storage and retrieval unit 318 to flow towards the distal end 326 of guide wire 304. After reaching the distal end of intake lumen 319, the cryogenic material flows through a junction connecting intake lumen 319 with exhaust lumen 323 at the distal end of the intake lumen
19
319 and exhaust lumen 323. The specific junction depicted in Figure 3 comprises an expansion chamber 324 within ablation probe 301 into which intake tumen 319 and exhaust lumen 323 open. Running substantially the length of guide wire 304, substantially parallel to intake lumen 319, and terminating at the proximal end 321 of guide wire 304, exhaust lumen 323 permits the cryogenic material to flow towards proximal end 321 of guide wire 304. After reaching the proximal end 321 of guide wire 304, the cryogenic material is returned to storage and retrieval unit 318 via cryogenic exhaust tubing 325 attached to the proximal end exhaust lumen 323, which is in fluid communication with storage and retrieval unit 318 and exhaust lumen 323. Cryogenic storage and retrieval may alternatively be accomplished by the simultaneous use of separate storage and retrieval units. The storage and retrieval unit may also permit the recycling of the employed cryogenic material as to reduce operation costs.
In order to prevent catheter 306 from becoming rigid and inflexible as cryogenic material flows through guide wire 304, catheter 306, or portion thereof, may be wrapped with a wire conducting an electrical current. The resistance in the wire to the flow of electricity may generate heat that warms catheter 306, thereby keeping it flexible. Alternatively, the warming wire may be wrapped around guide wire 304.
Figures 4A-4B depicts cross-sectional views of the proximal end of the embodiment of the ablative apparatus depicted in Figure 3. Figure 4 A depicts a cross- sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 extended from pocket 315. Figure 4B depicts a cross-sectional view of the embodiment of the apparatus depicted in Figure 3 with ablation probe 301 retracted into pocket 315. As previously stated in the discussion of Figure 3, guide wire 304 comprises
20
a cryogenic intake lumen 319 and an exhaust lumen 323 connected by expansion chamber 324. The flow of a cryogenic material from the proximal end 321 of guide wire 304 towards the distal end 326 of guide wire 304 through intake lumen b, across the junction formed by expansion chamber 324, and then back towards the proximal end 322 through exhaust lumen 323 cools ablation probe 301. It should be appreciated that in the alternative to the expansion chamber depicted in Figures 3 and 4, the junction between the intake lumen 319 and exhaust lumen 323 may comprise one or a series of ports connecting intake lumen 319 with exhaust lumen 323.
Incorporating threading on a portion of the ablation probe and/or transducer along with corresponding threading on the internal surface of the catheter's pocket may facilitate a smooth deployment of the ablation probe from the catheter's pocket. In such an embodiment, the surgeon would advance the ablation probe from the pocket by rotating the guide wire and attached ablation probe. Rotating the guide wire in the opposite direction would retract the ablation probe back into the pocket. The ablation probe of the ablative apparatus may contain one or multiple abrasive members attached to its proximal and/or radial surfaces. Furthermore, the abrasive members may be constructed in various configurations, as depicted in Figure 5.
Figure 5A-5D depicts various ablation probes each comprising a distal surface, a proximal surface opposite the distal surface, and a radial surface extending between the proximal surface and the distal surface, and abrasive members on a surface other than the proximal surface. The ablation probe 501, depicted in Figure 5A, contains an abrasive member comprising a thin band 502 attached to radial surface 503 and spiraling around ablation probe 501 similar to the threads of a screw. Alternatively, the ablation probe
21
504, as depicted in Figure 5B, may contain abrasive members comprising a thin band 505 attached to radial surface 506 and encircling ablation probe 504. As indicated by ablation probe 507, depicted in Figure 5C, it also possible for the abrasive member to comprise small particle 508, conceptually similar to a grain of grit on a piece of sand paper, attached to the proximal surface 509 and/or radial surface 510 of ablation probe 507. It is also possible, as indicated by ablation probe 511, depicted in Figure 5D, for the abrasive member to comprise a protrusion 512 extending from a surface of the ablation probe 511 other than proximal surface 513. It should be appreciated that the ablation probes depicted in Figures 5A-5D may be constructed by attaching or affixing the depicted abrasive members to their proximal and/or radial surfaces. Alternatively, the ablation probes depicted in Figures 5A-5D may be constructed such that the abrasive members are extensions of or integral with the ablation probes.
Figures 6A-6C depicts different piezo ceramic disc configurations that may be included within the transducer utilized to drive the ablation probe. The transducer may be comprised of a single piezo ceramic disc. Alternatively, the transducer may contain a collection of piezo ceramic discs as depicted in Figure 6. For instance, the transducer may contain a collection cylindrical piezo ceramic discs 601 stacked upon one another in a manner resembling a roll of coins, as depicted in Figure 6A. Such an arrangement may impart an axial or longitudinal displacement upon the driven ablation probe when the transducer is energized. Alternatively, the transducer may contain a pair of half cylindrical piezo ceramic discs 602 combined to form a cylinder, as depicted in Figure 6C. Such an arrangement may impart a circumferential displacement upon the driven ablation probe when the transducer is energized. The transducer may also contain a
22
combination of cylindrical piezo ceramic discs 601 and half cylindrical piezo ceramic discs 602, as depicted in Figure 6B. Such a combination arrangement may impart an axial and circumferential displacement upon the driven ablation probe when the transducer is energized. The ultrasound transducer responsible for driving the ablation probe need not be in direct contact with the ablation probe. Instead, the transducer may be in communication with the guide wire attached to the ablation probe, driving the ablation probe through said communication. In such an embodiment, the transducer may be located anywhere within the ablative apparatus, including, but not limited to, the handle. The transducer may also be located elsewhere within the ablative apparatus, provided the transducer is in direct or indirect communication with the ablation probe.
The transducer utilized in the ablative apparatus should be capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz. The recommended frequency of vibration is approximately 30 kHz to approximately 40 kHz. The transducer should also be capable of driving the transducer with ultrasonic energy having an intensity of at least approximately 0.1 Watts per centimeter squared.
Pulse duration and treatment time are dependent upon the depth and type of lesion the surgeon wishes to induce. Pulsing the ultrasound energy driving the transducer by repeatedly turning the transducer on and off gives the surgeon control over lesion depth. Incorporating an ultrasound controller may permit the surgeon to control, regulate, or adjust, the pulse duration and pulse frequency of the driving ultrasound. Adjusting the
23
pulse frequency and duration enables the surgeon to control the depth of the lesion inflicted by the ablation probe.
When the ablation probe has been advanced to the desired lesion location, the surgeon may retract the catheter as to expose the ablation probe's abrasive member(s). The surgeon may then mechanical induce an abrasion by driving the ablation probe with ultrasound energy generated by the transducer. Alternatively, the surgeon may not expose the ablation probe's abrasive members but rather activate the flow of cryogenic material through the ablative apparatus as to induce a lesion by means of cryoablation. If the surgeon wishes to induce a continuous lesion across a segment of cardiac tissue, the surgeon may activate the transducer as to prevent cryoadhesion of the catheter's distal end to the target tissue. Activating the transducer during cryoablation enables the surgeon to warm surface tissue at the site of ablation, thereby protecting surface tissue from ablation or injury. Likewise, activating the flow of cryogenic material through the apparatus while ultrasonically inducing a lesion enables the surgeon to cool surface tissue at the site of the ablation, thereby protecting it from ablation or injury.
Incorporating a mapping electrode placed at or near the distal end of the ablative apparatus may assist the surgeon in locating specific sites of arrhythmia. Alternatively, the mapping electrode may be located at or attached to the ablation probe. A mapping electrode may enable the surgeon to detect the electrical activity of the cells near the electrode. The surgeon could use the detected electrical activity to determine if the cells near the electrode are contributing to the arrhythmia. Furthermore, the surgeon may administer cryogenic energy to a region of myocardium suspected to be contributing to the patient's arrhythmia as to paralyze the tissue. If paralyzing the tissue completely or
24
partially corrects the arrhythmia, the surgeon may then ablate the tissue with the ablation probe.
Incorporating a temperature sensor placed at or near the distal end of the ablative apparatus may enable the surgeon to monitor the temperature at the site of the ablation. Alternatively, the sensor may be located near or attached to the ablation probe.
Monitoring the temperature near or at the site of the ablation with the temperature sensor may assist the surgeon in avoiding burning and/or inflicting other undesirable damage or injury. When the temperature of the tissue being ablated reaches or approaches an undesirable level, the surgeon could stop the ablation and allow the tissue to return to a safer temperature. The surgeon may also adjust the ultrasound parameters as to slow the change in temperature. If the ablative procedure being performed involves the administration of cryogenic energy, the surgeon may adjust the flow of the cryogenic material through the catheter system as to slow the change in temperature.
The ablative apparatus may also contain a drug lumen through which a drug solution or other fluid or composition may be introduced into the patient's body.
Ultrasonically driving the ablation probe, while simultaneously delivering drug through the apparatus by way of the drug lumen, may be utilized by the surgeon to facilitate the release of the drug from the apparatus, as well as the penetration of the drug into targeted tissue. The ablative apparatus may also contain a drug reservoir at its distal end. The drug reservoir may surround the ablation probe. Alternatively, the drug reservoir may be located proximal to the ablation probe. When located proximal to the ablation probe, the drug reservoir may contain slits at its base. The slits may completely or partially
25
penetrate the base of the drug reservoir. Retracting the catheter may then cause the ablation probe to penetrate the base of the drug reservoir and eventually the distal end of the reservoir. Traveling through the reservoir, the ablation probe may be coated with a drug. Suspending the drug within a viscous or gel solution may offer better coating of the ablation probe as it travels through the drug reservoir. Ultrasonically driving the ablation probe will cause the drug solution clinging to the ablation probe to be liberated from the ablation probe and embedded in the tissue at and surrounding the site of the lesion. Similarly, ultrasonically driving the ablation probe while the probe is retracted may cause the release of drug from the drug reservoir. Alternatively, drug delivery during the induction of lesions may be accomplished by first coating the ablation probe with a pharmacological compound. As in the above mention embodiment, ultrasonically driving the ablation probe will liberate the drug coating compound; dispersing it into the targeted tissue.
It should be appreciated that the term "biologically compatible polymer," as used herein, refers to polymers, or plastics, that will not normally irritate or harm the body. Such polymers are familiar to those skilled in the art.
It should be appreciate that term "piezo ceramic disc," as used herein, refers to an element composed of a ceramic material expands and contracts when exposed to an alternating voltage. Such ceramics are well known to those skilled in the art. It should be appreciated that "energizing the transducer," as used herein, refers to inducing the contraction and expansion of piezo ceramic discs within the transducer by exposing the discs to an alternating voltage, as to induce the generation of ultrasonic energy.
26
It should be appreciated that the term "ultrasonically driven," as used herein, refers to causing the ablation probe to move by applying to the probe ultrasonic energy generated by a transducer in direct or indirect contract with the probe. The induced movement of the probe may include vibrating, oscillating, and/or other manners of motion.
It should be appreciated that the term "pulse duration," as used herein, refers to the length of time the transducer is generating ultrasonic energy.
It should be appreciated that the term "pulse frequency," as used herein, refers to how often ultrasound transducer generates ultrasound during a period of time. It should be appreciated that the term "mechanical ablation," as used herein, refers to injuring a tissue by scratching the tissue as to create an abrasion in the tissue.
It should be appreciated that the term "surgeon," as used herein, references all potential users of the disclosed ablative apparatus and does not limit the user of the apparatus to any particular healthcare or medical professional or healthcare or medical professionals in general.
Although specific embodiments and methods of use have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that any arrangement that is calculated to achieve the same purpose may be substituted for the specific embodiments and methods shown. It is to be understood that the above description is intended to be illustrative and not restrictive. Combinations of the above embodiments and other embodiments as well as combinations of the above methods of use and other methods of use will be apparent to those having skill in the art upon review of the present disclosure. The scope of the present invention should be determined with
27
reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
INDUSTRIAL APPLICABILITY The disclosed ablative apparatus enables the surgical treatment of atrial fibrillation and/or other arrhythmias.
28
Claims
1. An ablative apparatus comprising: a. An ablation probe containing: i. a proximal surface; ii. a distal surface opposite the proximal surface; iii. at least on radial surface extending between the proximal surface and the distal surface; and iv. at least one abrasive member on a surface of the ablation probe other than the proximal surface; b. A transducer capable of ultrasonically driving the ablation probe in contact with the proximal surface of the ablation probe containing: i. at least one piezo ceramic disc; and ii. electrodes capable of exposing the piezo ceramic disc to an alternating voltage; c. A guide wire secured at one end to the transducer; d. A handle secured at the end of the guide wire opposite the transducer; e. Electrical leads running along the guide wire and connected to electrodes within the transducer; f. A catheter encasing the ablation probe, transducer, and at least a portion of the guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end;
29
iii. a pocket at the distal end of the catheter encasing the ablation probe; iv. a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter, v. a cryogenic exhaust lumen running substantially the length of the catheter, substantially parallel to the cryogenic intake lumen, and terminating at the proximal end of the catheter; vi. a junction connecting the intake lumen and exhaust lumen at the distal end intake and exhaust lumen; and vii. a partition distal to the junction isolating the intake lumen and exhaust lumen from the pocket encasing the ablation probe.
2. The apparatus according to Claim 1 further characterized by the catheter being composed of a biologically compatible polymer.
3. The apparatus according to Claim 1 further comprising a sealed tip at the distal end of the pocket encasing the ablation probe containing one or a plurality of slits at least partially penetrating the sealed tip.
4. The apparatus according to Claim 1 further characterized by the transducer containing a stack of piezo ceramic discs.
5. The apparatus according to Claim 1 further characterized by the transducer containing at least one pair of half cylindrical piezo ceramic discs combined to form a cylinder.
30
6. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a protrusion extending from a surface of the ablation probe other than its proximal surface.
7. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe spiraling around the ablation probe.
8. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe encircling the ablation probe. 9. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a small particle on a surface of the ablation probe other than its proximal surface.
10. The apparatus according to Claim 1 further characterized by the junction connecting the intake lumen and exhaust lumen of the catheter comprising at least one port connecting the intake and exhaust lumen.
11. The apparatus according to Claim 1 further comprising a cryogenic storage unit in fluid communication with the cryogenic intake lumen via cryogenic feed tubing attached to the proximal end of the intake lumen.
12. The apparatus according to Claim 1 further comprising a cryogenic retrieval unit in fluid communication with the cryogenic exhaust lumen via cryogenic exhaust tubing attached to the proximal end of the exhaust lumen.
31
13. The apparatus according to Claim 1 further characterized by the transducer being capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
14. An ablative apparatus comprising: a. A guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end; iii. a cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the guide wire; and iv. a cryogenic exhaust lumen running substantially the length of the guide wire, substantially parallel to the cryogenic intake lumen, and terminating at the proximal end of the guide wire; b. An ablation probe secured to the distal end of the guide wire containing: i. a proximal surface; ii. a distal surface opposite the proximal surface; iii. at least on radial surface extending between the proximal surface and the distal surface; iv. at least one abrasive member on a surface of the ablation probe other than the proximal surface; and v. an internal expansion chamber into which the intake lumen and exhaust lumen of the guide wire open;
32
c. A transducer capable of ultrasonically driving the ablation probe in contact with the proximal surface of the ablation probe and encircling the guide wire containing: i. at least one piezo ceramic disc; and ii. electrodes capable of exposing the piezo ceramic disc to an alternating voltage; d. A handle secured at the end of the guide wire opposite the ablation probe; e. Electrical leads running along the guide wire and connected to electrodes within the transducer; f. A catheter encasing the ablation probe, transducer, and at least a portion of the guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end; and iii. a pocket at the distal end of the catheter encasing the ablation probe;
15. The apparatus according to Claim 14 further characterized by the catheter being composed of a biologically compatible polymer.
16. The apparatus according to Claim 14 further comprising a sealed tip at the distal end of the pocket encasing the ablation probe containing one or a plurality of slits at least partially penetrating the sealed tip.
17. The apparatus according to Claim 14 further characterized by the transducer containing a stack of piezo ceramic discs.
33
18. The apparatus according to Claim 14 further characterized by the transducer containing at least one pair of half cylindrical piezo ceramic discs combined to form a cylinder.
19. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a protrusion extending from a surface of the ablation probe other than its proximal surface.
20. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe and spiraling around the ablation probe. 21. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe and encircling the ablation probe.
22. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a small particle on a surface of the ablation probe other than its proximal surface.
23. The apparatus according to Claim 1 further comprising a cryogenic storage unit in fluid communication with the cryogenic intake lumen via cryogenic feed tubing attached to the proximal end of the intake lumen.
24. The apparatus according to Claim 1 further comprising a cryogenic retrieval unit in fluid communication with the cryogenic exhaust lumen via cryogenic exhaust tubing attached to the proximal end of the exhaust lumen.
34
5. The apparatus according to Claim 1 further characterized by the transducer being capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
35
CLAIMS
I claim:
1. An ablative apparatus comprising: a. An ablation probe containing: i. a proximal surface; ii. a distal surface opposite the proximal surface; iii. at least on radial surface extending between the proximal surface and the distal surface; and iv. at least one abrasive member on a surface of the ablation probe other than the proximal surface; b. A transducer capable of ultrasonically driving the ablation probe in contact with the proximal surface of the ablation probe containing: i. at least one piezo ceramic disc; and ii. electrodes capable of exposing the piezo ceramic disc to an alternating voltage; c. A guide wire secured at one end to the transducer; d. A handle secured at the end of the guide wire opposite the transducer; e. Electrical leads running along the guide wire and connected to electrodes within the transducer; f. A catheter encasing the ablation probe, transducer, and at least a portion of the guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end;
29
iii. a pocket at the distal end of the catheter encasing the ablation probe; iv. a cryogenic intake lumen originating at the proximal end of the catheter and running substantially the length of the catheter; v. a cryogenic exhaust lumen running substantially the length of the catheter, substantially parallel to the cryogenic intake lumen, and terminating at the proximal end of the catheter; vi. a junction connecting the intake lumen and exhaust lumen at the distal end intake and exhaust lumen; and vii. a partition distal to the junction isolating the intake lumen and exhaust lumen from the pocket encasing the ablation probe.
2. The apparatus according to Claim 1 further characterized by the catheter being composed of a biologically compatible polymer.
3. The apparatus according to Claim 1 further comprising a sealed tip at the distal end of the pocket encasing the ablation probe containing one or a plurality of slits at least partially penetrating the sealed tip.
4. The apparatus according to Claim 1 further characterized by the transducer containing a stack of piezo ceramic discs.
5. The apparatus according to Claim 1 further characterized by the transducer containing at least one pair of half cylindrical piezo ceramic discs combined to form a cylinder.
30
6. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a protrusion extending from a surface of the ablation probe other than its proximal surface.
7. The apparatus according to Claim 1 further characterized by at least one abrasive 5 member on the ablation probe comprising a thin band on a radial surface of the ablation probe spiraling around the ablation probe.
8. The apparatus according to Claim 1 farther characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe encircling the ablation probe. 0
9. The apparatus according to Claim 1 further characterized by at least one abrasive member on the ablation probe comprising a small particle on a surface of the ablation probe other than its proximal surface.
10. The apparatus according to Claim 1 further characterized by the junction connecting the intake lumen and exhaust lumen of the catheter comprising at least S one port connecting the intake and exhaust lumen.
11. The apparatus according to Claim 1 further comprising a cryogenic storage unit in fluid communication with the cryogenic intake lumen via cryogenic feed tubing attached to the proximal end of the intake lumen.
12. The apparatus according to Claim 1 further comprising a cryogenic retrieval unit0 in fluid communication with the cryogenic exhaust lumen via cryogenic exhaust tubing attached to the proximal end of the exhaust lumen.
31
13. The apparatus according to Claim 1 further characterized by the transducer being capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
14. An ablative apparatus comprising: a. A guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end; iii. a cryogenic intake lumen originating at the proximal end of the guide wire and running substantially the length of the guide wire; and iv. a cryogenic exhaust lumen running substantially the length of the guide wire, substantially parallel to the cryogenic intake lumen, and terminating at the proximal end of the guide wire; b. An ablation probe secured to the distal end of the guide wire containing: i. a proximal surface; ii. a distal surface opposite the proximal surface; iii. at least on radial surface extending between the proximal surface and the distal surface; iv. at least one abrasive member on a surface of the ablation probe other than the proximal surface; and v. an internal expansion chamber into which the intake lumen and exhaust lumen of the guide wire open;
32
c. A transducer capable of ultrasonically driving the ablation probe in contact with the proximal surface of the ablation probe and encircling the guide wire containing: i. at least one piezo ceramic disc; and ii. electrodes capable of exposing the piezo ceramic disc to an alternating voltage; d. A handle secured at the end of the guide wire opposite the ablation probe; e. Electrical leads running along the guide wire and connected to electrodes within the transducer; f. A catheter encasing the ablation probe, transducer, and at least a portion of the guide wire containing: i. a proximal end; ii. a distal end opposite the proximal end; and iii. a pocket at the distal end of the catheter encasing the ablation probe;
15. The apparatus according to Claim 14 further characterized by the catheter being composed of a biologically compatible polymer.
16. The apparatus according to Claim 14 further comprising a sealed tip at the distal end of the pocket encasing the ablation probe containing one or a plurality of slits at least partially penetrating the sealed tip.
17. The apparatus according to Claim 14 further characterized by the transducer containing a stack of piezo ceramic discs.
33
18. The apparatus according to Claim 14 further characterized by the transducer containing at least one pair of half cylindrical piezo ceramic discs combined to form a cylinder.
19. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a protrusion extending from a surface of the ablation probe other than its proximal surface.
20. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe and spiraling around the ablation probe.
21. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a thin band on a radial surface of the ablation probe and encircling the ablation probe.
22. The apparatus according to Claim 14 further characterized by at least one abrasive member on the ablation probe comprising a small particle on a surface of the ablation probe other than its proximal surface.
23. The apparatus according to Claim 1 further comprising a cryogenic storage unit in fluid communication with the cryogenic intake lumen via cryogenic feed tubing attached to the proximal end of the intake lumen.
24. The apparatus according to Claim 1 further comprising a cryogenic retrieval unit in fluid communication with the cryogenic exhaust lumen via cryogenic exhaust tubing attached to the proximal end of the exhaust lumen.
34
5. The apparatus according to Claim 1 further characterized by the transducer being capable of inducing the ablation probe to vibrate at a frequency between approximately 20 kHz and approximately 20 MHz.
35
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/463,187 | 2006-08-08 | ||
US11/463,187 US20080039727A1 (en) | 2006-08-08 | 2006-08-08 | Ablative Cardiac Catheter System |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008021886A2 true WO2008021886A2 (en) | 2008-02-21 |
WO2008021886A3 WO2008021886A3 (en) | 2008-10-23 |
Family
ID=39051730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/075487 WO2008021886A2 (en) | 2006-08-08 | 2007-08-08 | Ablative cardiac catheter system |
Country Status (2)
Country | Link |
---|---|
US (3) | US20080039727A1 (en) |
WO (1) | WO2008021886A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009148807A1 (en) * | 2008-06-05 | 2009-12-10 | Cardiovascular Systems, Inc. | Cutting and coring atherectomy device and method |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
EP2452648B1 (en) | 2003-09-12 | 2016-02-10 | Vessix Vascular, Inc. | System for selectable eccentric remodeling and/or ablation of atherosclerotic material |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
WO2006063199A2 (en) | 2004-12-09 | 2006-06-15 | The Foundry, Inc. | Aortic valve repair |
US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
WO2007140331A2 (en) | 2006-05-25 | 2007-12-06 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US20080097251A1 (en) * | 2006-06-15 | 2008-04-24 | Eilaz Babaev | Method and apparatus for treating vascular obstructions |
US20080039727A1 (en) * | 2006-08-08 | 2008-02-14 | Eilaz Babaev | Ablative Cardiac Catheter System |
CA2666661C (en) | 2006-10-18 | 2015-01-20 | Minnow Medical, Inc. | Tuned rf energy and electrical tissue characterization for selective treatment of target tissues |
WO2008049087A2 (en) | 2006-10-18 | 2008-04-24 | Minnow Medical, Inc. | System for inducing desirable temperature effects on body tissue |
WO2008049082A2 (en) | 2006-10-18 | 2008-04-24 | Minnow Medical, Inc. | Inducing desirable temperature effects on body tissue |
US7823761B2 (en) * | 2007-05-16 | 2010-11-02 | The Invention Science Fund I, Llc | Maneuverable surgical stapler |
US7798385B2 (en) * | 2007-05-16 | 2010-09-21 | The Invention Science Fund I, Llc | Surgical stapling instrument with chemical sealant |
US7810691B2 (en) * | 2007-05-16 | 2010-10-12 | The Invention Science Fund I, Llc | Gentle touch surgical stapler |
US20080287987A1 (en) * | 2007-05-16 | 2008-11-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Dispensing system for tissue sealants |
US7922064B2 (en) * | 2007-05-16 | 2011-04-12 | The Invention Science Fund, I, LLC | Surgical fastening device with cutter |
US8485411B2 (en) | 2007-05-16 | 2013-07-16 | The Invention Science Fund I, Llc | Gentle touch surgical stapler |
US7832611B2 (en) * | 2007-05-16 | 2010-11-16 | The Invention Science Fund I, Llc | Steerable surgical stapler |
US20090112243A1 (en) * | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surgical cutter with dispensing system for tissue sealants |
US20090112256A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Suturing device with tissue sealant dispenser |
US20090143816A1 (en) * | 2007-11-30 | 2009-06-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Grasper with surgical sealant dispenser |
US8241324B2 (en) * | 2008-03-03 | 2012-08-14 | Eilaz Babaev | Ultrasonic vascular closure device |
WO2009149042A2 (en) * | 2008-06-03 | 2009-12-10 | Eilaz Babaev | Ultrasonic endometrial cryoablation device |
US20090312673A1 (en) * | 2008-06-14 | 2009-12-17 | Vytronus, Inc. | System and method for delivering energy to tissue |
US9089700B2 (en) | 2008-08-11 | 2015-07-28 | Cibiem, Inc. | Systems and methods for treating dyspnea, including via electrical afferent signal blocking |
WO2010056745A1 (en) | 2008-11-17 | 2010-05-20 | Minnow Medical, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
US7967814B2 (en) * | 2009-02-05 | 2011-06-28 | Icecure Medical Ltd. | Cryoprobe with vibrating mechanism |
WO2010144811A1 (en) * | 2009-06-11 | 2010-12-16 | Florida State University | Zero delta temperature thermal link |
US8795304B2 (en) * | 2009-06-18 | 2014-08-05 | Cardiovascular Systems, Inc. | Atherectomy device, system and method having a bi-directional distal expandable ablation element |
WO2011019947A1 (en) * | 2009-08-14 | 2011-02-17 | Boston Scientific Scimed, Inc. | Medical device comprising a catheter coupled to a conduct ive -fluid detector |
JP2013523318A (en) | 2010-04-09 | 2013-06-17 | べシックス・バスキュラー・インコーポレイテッド | Power generation and control equipment for tissue treatment |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
CN107349009B (en) | 2010-08-05 | 2020-06-26 | 美敦力Af卢森堡有限责任公司 | Cryoablation apparatus, systems, and methods for renal neuromodulation |
US20120095371A1 (en) * | 2010-10-18 | 2012-04-19 | CardioSonic Ltd. | Ultrasound transducer and cooling thereof |
EP2629848B1 (en) | 2010-10-18 | 2014-10-08 | Cardiosonic Ltd. | An ultrasound transceiver and control of a thermal damage process |
US9566456B2 (en) * | 2010-10-18 | 2017-02-14 | CardioSonic Ltd. | Ultrasound transceiver and cooling thereof |
US9028417B2 (en) | 2010-10-18 | 2015-05-12 | CardioSonic Ltd. | Ultrasound emission element |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US20120158104A1 (en) | 2010-10-26 | 2012-06-21 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
CA2832311A1 (en) | 2011-04-08 | 2012-11-29 | Covidien Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
CN103930061B (en) | 2011-04-25 | 2016-09-14 | 美敦力阿迪安卢森堡有限责任公司 | Relevant low temperature sacculus for restricted conduit wall cryogenic ablation limits the device and method disposed |
WO2013013156A2 (en) | 2011-07-20 | 2013-01-24 | Boston Scientific Scimed, Inc. | Percutaneous devices and methods to visualize, target and ablate nerves |
EP2734264B1 (en) | 2011-07-22 | 2018-11-21 | Boston Scientific Scimed, Inc. | Nerve modulation system with a nerve modulation element positionable in a helical guide |
WO2013055826A1 (en) | 2011-10-10 | 2013-04-18 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
US9079000B2 (en) | 2011-10-18 | 2015-07-14 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
CN108095821B (en) | 2011-11-08 | 2021-05-25 | 波士顿科学西美德公司 | Orifice renal nerve ablation |
WO2013074813A1 (en) | 2011-11-15 | 2013-05-23 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
AU2012358143B2 (en) | 2011-12-23 | 2015-06-11 | Boston Scientific Scimed, Inc. | Expandable balloon or an electrode pad with a heat sensing device |
US9433760B2 (en) | 2011-12-28 | 2016-09-06 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9566105B2 (en) | 2012-02-07 | 2017-02-14 | Cpsi Holdings Llc | Dual thermal ablation device and method of use |
WO2013157011A2 (en) * | 2012-04-18 | 2013-10-24 | CardioSonic Ltd. | Tissue treatment |
DE112013002175T5 (en) | 2012-04-24 | 2015-01-22 | Cibiem, Inc. | Endovascular catheters and procedures for ablation of the carotid body |
EP2840991B1 (en) | 2012-04-27 | 2019-05-15 | Medtronic Ardian Luxembourg S.à.r.l. | Cryotherapeutic devices for renal neuromodulation |
US9241752B2 (en) | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US10660703B2 (en) | 2012-05-08 | 2020-05-26 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
US11357447B2 (en) | 2012-05-31 | 2022-06-14 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
WO2013181660A1 (en) | 2012-06-01 | 2013-12-05 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
US9398930B2 (en) | 2012-06-01 | 2016-07-26 | Cibiem, Inc. | Percutaneous methods and devices for carotid body ablation |
CN104540465A (en) | 2012-08-24 | 2015-04-22 | 波士顿科学西美德公司 | Intravascular catheter with a balloon comprising separate microporous regions |
WO2014043687A2 (en) | 2012-09-17 | 2014-03-20 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
WO2014047411A1 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
WO2014047454A2 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
JP6074051B2 (en) | 2012-10-10 | 2017-02-01 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Intravascular neuromodulation system and medical device |
WO2014163987A1 (en) | 2013-03-11 | 2014-10-09 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
WO2014143571A1 (en) | 2013-03-11 | 2014-09-18 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
CN105228546B (en) | 2013-03-15 | 2017-11-14 | 波士顿科学国际有限公司 | Utilize the impedance-compensated medicine equipment and method that are used to treat hypertension |
US9827039B2 (en) | 2013-03-15 | 2017-11-28 | Boston Scientific Scimed, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
WO2014188430A2 (en) | 2013-05-23 | 2014-11-27 | CardioSonic Ltd. | Devices and methods for renal denervation and assessment thereof |
EP3010437A1 (en) | 2013-06-21 | 2016-04-27 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
JP2016524949A (en) | 2013-06-21 | 2016-08-22 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Medical device for renal nerve ablation having a rotatable shaft |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
AU2014284558B2 (en) | 2013-07-01 | 2017-08-17 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10660698B2 (en) | 2013-07-11 | 2020-05-26 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
EP3019106A1 (en) | 2013-07-11 | 2016-05-18 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
EP3049007B1 (en) | 2013-07-19 | 2019-06-12 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
WO2015013205A1 (en) | 2013-07-22 | 2015-01-29 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
JP6122217B2 (en) | 2013-07-22 | 2017-04-26 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Renal nerve ablation medical device |
CN105473093B (en) | 2013-08-22 | 2019-02-05 | 波士顿科学国际有限公司 | Flexible circuit with the improved adhesion strength to renal nerve modulation sacculus |
CN105555218B (en) | 2013-09-04 | 2019-01-15 | 波士顿科学国际有限公司 | With radio frequency (RF) foley's tube rinsed with cooling capacity |
EP3043733A1 (en) | 2013-09-13 | 2016-07-20 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
US9687166B2 (en) | 2013-10-14 | 2017-06-27 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
WO2015057584A1 (en) | 2013-10-15 | 2015-04-23 | Boston Scientific Scimed, Inc. | Medical device balloon |
WO2015057961A1 (en) | 2013-10-18 | 2015-04-23 | Boston Scientific Scimed, Inc. | Balloon catheters with flexible conducting wires and related methods of use and manufacture |
WO2015061457A1 (en) | 2013-10-25 | 2015-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
WO2015103617A1 (en) | 2014-01-06 | 2015-07-09 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
EP3102136B1 (en) | 2014-02-04 | 2018-06-27 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
WO2015138795A1 (en) | 2014-03-12 | 2015-09-17 | Cibiem, Inc. | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
CN110505900A (en) | 2017-03-20 | 2019-11-26 | 索尼伟业有限公司 | Method for treating heart failure by the ejection fraction for improving patient |
US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
US11633224B2 (en) | 2020-02-10 | 2023-04-25 | Icecure Medical Ltd. | Cryogen pump |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139496A (en) * | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB998173A (en) * | 1963-02-04 | 1965-07-14 | George Andrew Douglas Gordon | Method and apparatus for destroying limited groups of cells |
NL129743C (en) * | 1962-04-30 | 1900-01-01 | ||
NL145136C (en) * | 1967-07-25 | 1900-01-01 | ||
DE2219790C3 (en) * | 1972-04-22 | 1974-11-07 | R Pohlman | Device for generating brittle fractures in hard stones |
US4022215A (en) * | 1973-12-10 | 1977-05-10 | Benson Jerrel W | Cryosurgical system |
US3889680A (en) * | 1974-02-07 | 1975-06-17 | Armao T A | Cryoadhesion preventing cryosurgical instruments |
US4015606A (en) * | 1975-09-09 | 1977-04-05 | Dynatech Corporation | Method and means for controlling the freeze zone of a cryosurgical probe |
US4202336A (en) * | 1976-05-14 | 1980-05-13 | Erbe Elektromedizin Kg | Cauterizing probes for cryosurgery |
US4528979A (en) * | 1982-03-18 | 1985-07-16 | Kievsky Nauchno-Issledovatelsky Institut Otolaringologii Imeni Professora A.S. Kolomiiobenka | Cryo-ultrasonic surgical instrument |
US4582181A (en) * | 1983-08-12 | 1986-04-15 | Advanced Cardiovascular Systems, Inc. | Steerable dilatation catheter |
SU1417868A1 (en) * | 1985-11-20 | 1988-08-23 | Томский государственный медицинский институт | Cryoultrasonic scalpel |
SU1563684A1 (en) * | 1986-05-26 | 1990-05-15 | Томский государственный медицинский институт | Cryosurgical scalpel |
US4749376A (en) * | 1986-10-24 | 1988-06-07 | Intravascular Surgical Instruments, Inc. | Reciprocating working head catheter |
US5108390A (en) * | 1988-11-14 | 1992-04-28 | Frigitronics, Inc. | Flexible cryoprobe |
US4960134A (en) * | 1988-11-18 | 1990-10-02 | Webster Wilton W Jr | Steerable catheter |
GB2226497B (en) * | 1988-12-01 | 1992-07-01 | Spembly Medical Ltd | Cryosurgical probe |
US4946460A (en) * | 1989-04-26 | 1990-08-07 | Cryo Instruments, Inc. | Apparatus for cryosurgery |
US5076276A (en) * | 1989-11-01 | 1991-12-31 | Olympus Optical Co., Ltd. | Ultrasound type treatment apparatus |
US5211646A (en) * | 1990-03-09 | 1993-05-18 | Alperovich Boris I | Cryogenic scalpel |
ZA917281B (en) * | 1990-09-26 | 1992-08-26 | Cryomedical Sciences Inc | Cryosurgical instrument and system and method of cryosurgery |
US5261399A (en) | 1991-05-22 | 1993-11-16 | Klatz Ronald M | Brain cooling device and method for performing the same |
US6030412A (en) | 1991-05-22 | 2000-02-29 | Life Science Holdings, Inc. | Apparatus and method for cooling the brain, brain stem and associated neurologic tissues |
US5520682A (en) | 1991-09-06 | 1996-05-28 | Cryomedical Sciences, Inc. | Cryosurgical instrument with vent means and method using same |
US5423807A (en) * | 1992-04-16 | 1995-06-13 | Implemed, Inc. | Cryogenic mapping and ablation catheter |
US5281215A (en) * | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Cryogenic catheter |
US5295484A (en) * | 1992-05-19 | 1994-03-22 | Arizona Board Of Regents For And On Behalf Of The University Of Arizona | Apparatus and method for intra-cardiac ablation of arrhythmias |
WO1994002077A2 (en) * | 1992-07-15 | 1994-02-03 | Angelase, Inc. | Ablation catheter system |
US5362309A (en) | 1992-09-14 | 1994-11-08 | Coraje, Inc. | Apparatus and method for enhanced intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis |
US5319496A (en) * | 1992-11-18 | 1994-06-07 | Photonics Research Incorporated | Optical beam delivery system |
ATE178218T1 (en) | 1993-02-05 | 1999-04-15 | Joe W And Dorothy Dorsett Brow | ULTRASONIC BALLOON CATHETER FOR ANGIOPLASTY |
US5433717A (en) * | 1993-03-23 | 1995-07-18 | The Regents Of The University Of California | Magnetic resonance imaging assisted cryosurgery |
NL9301851A (en) | 1993-10-26 | 1995-05-16 | Cordis Europ | Cryo-ablation catheter. |
JP2891093B2 (en) * | 1994-02-17 | 1999-05-17 | 日本電気株式会社 | Manufacturing method of semiconductor integrated circuit |
US5672172A (en) * | 1994-06-23 | 1997-09-30 | Vros Corporation | Surgical instrument with ultrasound pulse generator |
US5452582A (en) * | 1994-07-06 | 1995-09-26 | Apd Cryogenics, Inc. | Cryo-probe |
US5514086A (en) * | 1994-09-22 | 1996-05-07 | Sonique Surgical Systems, Inc. | Multipiece ultrasonic probe for liposuction |
US6689086B1 (en) * | 1994-10-27 | 2004-02-10 | Advanced Cardiovascular Systems, Inc. | Method of using a catheter for delivery of ultrasonic energy and medicament |
US5928218A (en) * | 1994-12-16 | 1999-07-27 | Gelbfish; Gary A. | Medical material removal method and associated instrumentation |
US6936024B1 (en) * | 1995-01-23 | 2005-08-30 | Russell A. Houser | Percutaneous transmyocardial revascularization (PTMR) system |
DE19504261A1 (en) * | 1995-02-09 | 1996-09-12 | Krieg Gunther | Angioplasty catheter for dilating and / or opening blood vessels |
US5824005A (en) * | 1995-08-22 | 1998-10-20 | Board Of Regents, The University Of Texas System | Maneuverable electrophysiology catheter for percutaneous or intraoperative ablation of cardiac arrhythmias |
US5649936A (en) | 1995-09-19 | 1997-07-22 | Real; Douglas D. | Stereotactic guide apparatus for use with neurosurgical headframe |
US5735811A (en) * | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
US5728062A (en) * | 1995-11-30 | 1998-03-17 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
US6254622B1 (en) | 1996-02-20 | 2001-07-03 | Larry Hood | Blade for ultrasonically assisted cutting and hemostasis |
US5904709A (en) * | 1996-04-17 | 1999-05-18 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microwave treatment for cardiac arrhythmias |
US5716353A (en) | 1996-05-03 | 1998-02-10 | Urds, Corp. | Cryosurgical instrument |
US6039730A (en) | 1996-06-24 | 2000-03-21 | Allegheny-Singer Research Institute | Method and apparatus for cryosurgery |
US6505629B1 (en) * | 1996-07-23 | 2003-01-14 | Endocare, Inc. | Cryosurgical system with protective warming feature |
US5800488A (en) | 1996-07-23 | 1998-09-01 | Endocare, Inc. | Cryoprobe with warming feature |
US6080170A (en) * | 1996-07-26 | 2000-06-27 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US5976123A (en) | 1996-07-30 | 1999-11-02 | Laser Aesthetics, Inc. | Heart stabilization |
US5916242A (en) | 1996-11-04 | 1999-06-29 | Schwartz; George R. | Apparatus for rapid cooling of the brain and method of performing same |
US5794629A (en) * | 1996-11-27 | 1998-08-18 | The Regents Of The University Of California | Method for treating ischemic brain stroke |
US6221038B1 (en) * | 1996-11-27 | 2001-04-24 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
US5985057A (en) * | 1996-11-29 | 1999-11-16 | Sanyo Electric Co., Ltd. | Method of fabricating hydrogen absorbing alloy electrode |
US5910104A (en) * | 1996-12-26 | 1999-06-08 | Cryogen, Inc. | Cryosurgical probe with disposable sheath |
US5899898A (en) | 1997-02-27 | 1999-05-04 | Cryocath Technologies Inc. | Cryosurgical linear ablation |
US7220257B1 (en) * | 2000-07-25 | 2007-05-22 | Scimed Life Systems, Inc. | Cryotreatment device and method |
US6086582A (en) | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
US6416510B1 (en) * | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6041787A (en) | 1997-03-17 | 2000-03-28 | Rubinsky; Boris | Use of cryoprotective agent compounds during cryosurgery |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US5792140A (en) | 1997-05-15 | 1998-08-11 | Irvine Biomedical, Inc. | Catheter having cooled multiple-needle electrode |
US5843152A (en) | 1997-06-02 | 1998-12-01 | Irvine Biomedical, Inc. | Catheter system having a ball electrode |
US5876399A (en) | 1997-05-28 | 1999-03-02 | Irvine Biomedical, Inc. | Catheter system and methods thereof |
US6226554B1 (en) * | 1997-06-02 | 2001-05-01 | Hosheng Tu | Catheter system having a ball electrode and methods thereof |
US5906612A (en) | 1997-09-19 | 1999-05-25 | Chinn; Douglas O. | Cryosurgical probe having insulating and heated sheaths |
US6007514A (en) * | 1997-09-30 | 1999-12-28 | Nita; Henry | Ultrasound system with pathfinding guidewire |
US6120500A (en) * | 1997-11-12 | 2000-09-19 | Daig Corporation | Rail catheter ablation and mapping system |
US6083166A (en) | 1997-12-02 | 2000-07-04 | Situs Corporation | Method and apparatus for determining a measure of tissue manipulation |
US6280441B1 (en) * | 1997-12-15 | 2001-08-28 | Sherwood Services Ag | Apparatus and method for RF lesioning |
CA2318243A1 (en) * | 1998-01-12 | 1999-07-15 | Ronald P. Lesser | Technique for using brain heat flow management to treat brain disorders |
US6231595B1 (en) * | 1998-03-31 | 2001-05-15 | Innercool Therapies, Inc. | Circulating fluid hypothermia method and apparatus |
US6051019A (en) | 1998-01-23 | 2000-04-18 | Del Mar Medical Technologies, Inc. | Selective organ hypothermia method and apparatus |
US6096068A (en) * | 1998-01-23 | 2000-08-01 | Innercool Therapies, Inc. | Selective organ cooling catheter and method of using the same |
US6045532A (en) | 1998-02-20 | 2000-04-04 | Arthrocare Corporation | Systems and methods for electrosurgical treatment of tissue in the brain and spinal cord |
US6905494B2 (en) * | 1998-03-31 | 2005-06-14 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing tissue protection |
US6602276B2 (en) * | 1998-03-31 | 2003-08-05 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation |
US7001378B2 (en) * | 1998-03-31 | 2006-02-21 | Innercool Therapies, Inc. | Method and device for performing cooling or cryo-therapies, for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing tissue protection |
US6106518A (en) * | 1998-04-09 | 2000-08-22 | Cryocath Technologies, Inc. | Variable geometry tip for a cryosurgical ablation device |
US6126684A (en) * | 1998-04-21 | 2000-10-03 | The Regents Of The University Of California | Indwelling heat exchange catheter and method of using same |
US6045550A (en) * | 1998-05-05 | 2000-04-04 | Cardiac Peacemakers, Inc. | Electrode having non-joined thermocouple for providing multiple temperature-sensitive junctions |
US6527767B2 (en) * | 1998-05-20 | 2003-03-04 | New England Medical Center | Cardiac ablation system and method for treatment of cardiac arrhythmias and transmyocardial revascularization |
US6203540B1 (en) * | 1998-05-28 | 2001-03-20 | Pearl I, Llc | Ultrasound and laser face-lift and bulbous lysing device |
US6217518B1 (en) * | 1998-10-01 | 2001-04-17 | Situs Corporation | Medical instrument sheath comprising a flexible ultrasound transducer |
US6033403A (en) | 1998-10-08 | 2000-03-07 | Irvine Biomedical, Inc. | Long electrode catheter system and methods thereof |
US6565556B1 (en) * | 1999-02-12 | 2003-05-20 | Nikolai Korpan | Device for carrying out cryosurgical interventions, especially for treating tumors |
US6546932B1 (en) * | 1999-04-05 | 2003-04-15 | Cryocath Technologies Inc. | Cryogenic method and apparatus for promoting angiogenesis |
US6702811B2 (en) * | 1999-04-05 | 2004-03-09 | Medtronic, Inc. | Ablation catheter assembly with radially decreasing helix and method of use |
US20010007940A1 (en) * | 1999-06-21 | 2001-07-12 | Hosheng Tu | Medical device having ultrasound imaging and therapeutic means |
US6283959B1 (en) * | 1999-08-23 | 2001-09-04 | Cyrocath Technologies, Inc. | Endovascular cryotreatment catheter |
US6607520B2 (en) * | 1999-09-15 | 2003-08-19 | The General Hospital Corporation | Coiled ablation catheter system |
US20040097996A1 (en) * | 1999-10-05 | 2004-05-20 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode |
US6379371B1 (en) * | 1999-11-15 | 2002-04-30 | Misonix, Incorporated | Ultrasonic cutting blade with cooling |
US6443969B1 (en) * | 2000-08-15 | 2002-09-03 | Misonix, Inc. | Ultrasonic cutting blade with cooling |
US7097641B1 (en) * | 1999-12-09 | 2006-08-29 | Cryocath Technologies Inc. | Catheter with cryogenic and heating ablation |
US6743222B2 (en) * | 1999-12-10 | 2004-06-01 | Candela Corporation | Method of treating disorders associated with sebaceous follicles |
US6413263B1 (en) * | 2000-04-24 | 2002-07-02 | Axon Instruments, Inc. | Stereotactic probe holder and method of use |
US6551309B1 (en) * | 2000-09-14 | 2003-04-22 | Cryoflex, Inc. | Dual action cryoprobe and methods of using the same |
US6527765B2 (en) * | 2000-10-06 | 2003-03-04 | Charles D. Kelman | Cryogenic surgical system and method of use in removal of tissue |
US6457212B1 (en) * | 2001-02-07 | 2002-10-01 | Hans Oetiker Ag Maschinen- Und Apparatefabrik | Method of making hose clamps with internal clamping surfaces devoid of steps or gaps and products made by such method |
US6648880B2 (en) * | 2001-02-16 | 2003-11-18 | Cryocath Technologies Inc. | Method of using cryotreatment to treat brain tissue |
US6478754B1 (en) * | 2001-04-23 | 2002-11-12 | Advanced Medical Applications, Inc. | Ultrasonic method and device for wound treatment |
US7135029B2 (en) * | 2001-06-29 | 2006-11-14 | Makin Inder Raj S | Ultrasonic surgical instrument for intracorporeal sonodynamic therapy |
US6936045B2 (en) * | 2001-09-20 | 2005-08-30 | Endocare, Inc. | Malleable cryosurgical probe |
US20040249372A1 (en) * | 2001-09-26 | 2004-12-09 | Leonilda Capuano | Method for treatment of aneurysms |
US6709431B2 (en) * | 2001-12-18 | 2004-03-23 | Scimed Life Systems, Inc. | Cryo-temperature monitoring |
US20030204199A1 (en) * | 2002-04-30 | 2003-10-30 | Novak Theodore A. D. | Device and method for ultrasonic tissue excision with tissue selectivity |
US20050038420A1 (en) * | 2002-05-20 | 2005-02-17 | M.A.J.M. Huybregts | Cooling cannula system and method for use in cardiac surgery |
US6858025B2 (en) * | 2002-08-06 | 2005-02-22 | Medically Advanced Designs, Llc | Cryo-surgical apparatus and method of use |
US20040030254A1 (en) * | 2002-08-07 | 2004-02-12 | Eilaz Babaev | Device and method for ultrasound wound debridement |
US6942677B2 (en) * | 2003-02-26 | 2005-09-13 | Flowcardia, Inc. | Ultrasound catheter apparatus |
US7156816B2 (en) * | 2002-11-26 | 2007-01-02 | Biosense, Inc. | Ultrasound pulmonary vein isolation |
WO2005044124A1 (en) * | 2003-10-30 | 2005-05-19 | Medical Cv, Inc. | Apparatus and method for laser treatment |
US7238180B2 (en) * | 2003-10-30 | 2007-07-03 | Medicalcv Inc. | Guided ablation with end-fire fiber |
US7351219B2 (en) * | 2004-01-08 | 2008-04-01 | Alcon, Inc. | Method and instrumentation for cooling a surgical incision |
WO2006007305A2 (en) * | 2004-06-07 | 2006-01-19 | Edwards Lifesciences Corporation | Methods and devices for directionally ablating tissue |
US7572268B2 (en) * | 2005-10-13 | 2009-08-11 | Bacoustics, Llc | Apparatus and methods for the selective removal of tissue using combinations of ultrasonic energy and cryogenic energy |
US20080039727A1 (en) * | 2006-08-08 | 2008-02-14 | Eilaz Babaev | Ablative Cardiac Catheter System |
-
2006
- 2006-08-08 US US11/463,187 patent/US20080039727A1/en not_active Abandoned
-
2007
- 2007-08-08 WO PCT/US2007/075487 patent/WO2008021886A2/en active Application Filing
- 2007-08-27 US US11/845,220 patent/US7540870B2/en not_active Expired - Fee Related
-
2009
- 2009-04-24 US US12/429,660 patent/US8062289B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139496A (en) * | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009148807A1 (en) * | 2008-06-05 | 2009-12-10 | Cardiovascular Systems, Inc. | Cutting and coring atherectomy device and method |
EP2303151A1 (en) * | 2008-06-05 | 2011-04-06 | Cardiovascular Systems, Inc. | Cutting and coring atherectomy device and method |
CN102056557A (en) * | 2008-06-05 | 2011-05-11 | 心血管系统公司 | Cutting and coring atherectomy device and method |
EP2303151A4 (en) * | 2008-06-05 | 2011-11-30 | Cardivascular Systems | Cutting and coring atherectomy device and method |
US8192451B2 (en) | 2008-06-05 | 2012-06-05 | Cardiovascular Systems, Inc. | Cutting and coring atherectomy device and method |
AU2009255435B2 (en) * | 2008-06-05 | 2014-08-21 | Cardiovascular Systems, Inc. | Cutting and coring atherectomy device and method |
Also Published As
Publication number | Publication date |
---|---|
US8062289B2 (en) | 2011-11-22 |
US20090209885A1 (en) | 2009-08-20 |
US20080039727A1 (en) | 2008-02-14 |
US7540870B2 (en) | 2009-06-02 |
WO2008021886A3 (en) | 2008-10-23 |
US20080039745A1 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7540870B2 (en) | Ablative ultrasonic-cryogenic apparatus | |
US20090221955A1 (en) | Ablative ultrasonic-cryogenic methods | |
JP7033142B2 (en) | Pulmonary vein isolation balloon catheter | |
JP5054116B2 (en) | Vacuum coagulation probe | |
JP2501409B2 (en) | Device and method for intracardiac removal of arrhythmias | |
CA2726934C (en) | System and method for delivering energy to tissue | |
EP1750804B1 (en) | System of using high intensity focused ultrasound to form an ablated tissue area | |
US7294143B2 (en) | Device and method for ablation of cardiac tissue | |
US6719770B2 (en) | Ultrasonic device for providing reversible tissue damage to heart muscle | |
US7706882B2 (en) | Methods of using high intensity focused ultrasound to form an ablated tissue area | |
JP5320065B2 (en) | Suction type coagulation probe | |
US7118566B2 (en) | Device and method for needle-less interstitial injection of fluid for ablation of cardiac tissue | |
Avitall et al. | Physics and engineering of transcatheter cardiac tissue ablation | |
US5462544A (en) | Continuous heart tissue mapping and lasing catheter | |
US5824005A (en) | Maneuverable electrophysiology catheter for percutaneous or intraoperative ablation of cardiac arrhythmias | |
JP2001521774A (en) | Ring-shaped electrode structure for diagnostic and ablation catheters | |
CA2727025A1 (en) | Handheld system and method for delivering energy to tissue | |
JP2023528084A (en) | Ablation device for treating target areas of tissue within an organ | |
WO2005034782A2 (en) | Device and method for ablation of cardiac tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07813899 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07813899 Country of ref document: EP Kind code of ref document: A2 |